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Abstract 
 
Microspheres composed of poly(lactic-co-glycolic acid) (PLGA) have been a 
major area of interest for vaccine delivery due to their ability for (1) controlled release of 
antigen, which may enable a decrease in the number of doses required for protective 
immunity, and (2) enhancing the immune response against poorly immunogenic antigens. 
One disadvantage to this delivery system is that antigens encapsulated within PLGA 
microspheres by traditional techniques are susceptible to instability due to harsh 
processing conditions, including shear stress and exposure to organic solvent. Our lab has 
developed a novel method, termed “self-encapsulation,” for the remote loading of large 
molecules into pre-made PLGA microspheres. These microspheres contain a protein-
trapping agent and interconnecting pore network. Simple mixing of the microspheres in 
an aqueous solution of the antigen enables the protein to diffuse into the polymer pores 
and bind to the trapping agent. Subsequent heating of the system above the glass 
transition temperature (Tg) of the polymer causes the pores to close, sealing the protein 
inside the microspheres. This project further expands upon the self-encapsulation 
approach by exploring its application to vaccine delivery. A formulation of self-
encapsulating microspheres was developed for internalization by antigen-presenting cells 
(APCs), key cells for antigen processing and adaptive immunity. Using ovalbumin as a 
model antigen, formulation characteristics, including self-encapsulation ability and 
 xviii 
protein release kinetics, were defined. Stability of encapsulated protein was investigated 
and maintenance of antigenicity during release was confirmed. In vitro studies showed 
successful internalization of the microspheres by murine APCs. To examine the type and 
magnitude of the immune response induced by the microspheres, C57BL/6 mice were 
immunized with the formulation by intranasal and subcutaneous administration. 
Intranasal delivery of the microspheres resulted in a Th2-skewed response in serum and 
local mucosa. In comparison, subcutaneous delivery of the formulation resulted in a 
significant ovalbumin-specific cellular immune response and serum IgG subclass titers 
associated with a mixed Th1/Th2 response. Additionally, the microspheres showed 
promising ability for single-time injection, which could improve convenience and patient 
compliance. Due to the results of our studies, this formulation of self-encapsulating 
microspheres was concluded to have potential for further vaccine development. 
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Chapter 1 
Introduction 
1.1 Motivation 
Vaccines are one of the most successful public health interventions, with an 
estimated 2-3 million deaths alone averted each year due to immunization against 
diphtheria, pertussis, tetanus, and measles [1]. Despite this, there are still many 
challenges to overcome in regards to vaccine coverage and protection from infectious 
diseases. Factors including the vaccine delivery method (e.g. administration by needle), 
product thermostability during storage and transport, and multiple doses for full 
immunization all affect the completeness of vaccine coverage [2]. In addition, there is 
also a need for new and improved vaccines. There are some infectious diseases for which 
vaccines are nonexistent and others for which the vaccines could be made more effective 
in their protective immune response ([2], [3]).  
Following these challenges in vaccine coverage and efficacy has come the 
development of novel approaches to vaccine delivery, with the goal of improving vaccine 
performance [3]. Antigen delivery systems (e.g. microspheres, nanoparticles, and 
liposomes) and adjuvants (e.g. aluminum and calcium compounds) have been widely 
explored as approaches to improve the immune response generated by the antigen. This is 
especially true for subunit- and recombinant protein-based vaccines, which are generally 
poorly immunogenic on their own, namely due to difficulty activating antigen-presenting 
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cells and their short in vivo half-life ([4], [5]). Adjuvants and delivery systems can 
improve antibody- and cell-mediated immunity, decrease the amount of antigen required 
in a dose, and decrease the number of doses necessary for immunization, among other 
benefits [3].  
Polymeric microspheres and nanoparticles have been widely researched for their 
use as vaccine delivery systems. One of the most commonly used polymers for this 
application is poly(lactic-co-glycolic acid) (PLGA), a biodegradable and biocompatible 
polymer ([4], [6]). PLGA particles are advantageous in their ability to control antigen 
delivery in both time and location [7]. The kinetics of PLGA degradation in the body can 
be tuned by the ratio of lactic to glycolic acid in the polymer [6]. By controlling the rate 
of degradation, one can also control the rate of release of the antigen cargo and exposure 
of the antigen to the immune system. For example, the release can be made continuous to 
mimic an infection or pulsatile to mimic booster administration [7]. The particles can also 
control where the antigen is delivered, such as directly to antigen-presenting cells (APCs), 
protecting the antigen from degradation until it is delivered to the cell ([7], [6]). 
Despite the benefits of PLGA particles, there are a number of challenges facing 
the development of this delivery system. One of the key challenges is antigen instability, 
which can occur during microsphere production, lyophilization and storage of the 
microspheres, and during antigen release [8]. Traditional microsphere production 
methods, during which the antigen is encapsulated by the polymer, expose the antigen to 
detrimental conditions. These include forces from emulsification procedures and 
exposure to aqueous/organic solvent interfaces ([8],[9]). Protein instability takes such 
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forms as aggregation and protein unfolding (i.e. loss of native structure) ([10], [11]). 
These factors create quite a task for delivering protein in its antigenic state.  
In an effort to improve protein stability in PLGA particles, the Schwendeman 
group has developed an encapsulation paradigm, termed “self-healing 
microencapsulation” or “self-encapsulation,” that bypasses many of the challenges of 
traditional PLGA encapsulation techniques ([8], [9]). This method relies on simple 
aqueous mixing of the antigen with pre-formed PLGA particles to load the antigen into 
the microspheres, thereby avoiding many sources of destabilization. The antigen does not 
encounter the detrimental shear stresses for emulsification, organic solvent, or phase 
interfaces characteristic of traditional encapsulation [9]. 
In this work, we investigate the application of self-healing microencapsulation to 
the delivery of vaccine antigens. Due to its gentle processing conditions, self- 
encapsulation is a promising approach for maintaining the stability and immunogenicity 
of encapsulated antigens ([8],[9]). For this project, a self-encapsulating PLGA 
microsphere formulation was developed for internalization by dendritic cells, key 
antigen-presenting cells. We specifically explore the type of in vivo immune response 
generated in mice after subcutaneous and intranasal administration of the microsphere 
formulation.  
1.2 An Overview of the Immune Response 
In order to appreciate the role that antigen delivery systems, such as PLGA 
microspheres, play in vaccine delivery, it is important to understand how the immune 
system operates. The immune system can be divided into two arms: the innate and the 
adaptive immune response, known respectively as “natural” and “acquired” immunity 
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[12]. These two systems work together to recognize and eliminate a threat and protect 
from re-infection ([13],[6]).  
1.2.1 Innate and Adaptive Immunity 
Though the innate and adaptive responses behave as an integrated system, it is the 
innate immune response that acts as a first line of defense against invading 
microorganisms. Its purpose is to recognize the presence of a pathogen and then eliminate 
the pathogen through mechanisms that include chemical mediators and effector cells, 
which fight against the pathogen in a non-specific way [5]. The innate immune system 
reacts quickly, usually within a few hours, and is responsible for differentiating self from 
infectious non-self and relaying this information to the adaptive immune system [5].  
Pathogen detection is achieved through non-specific receptors on innate immune 
cells, which recognize pathogen-associated structures. These structures, known as 
pathogen-associated molecular patterns (PAMPs), are recognized by pattern recognition 
receptors (PRRs) on effector cells [13]. PRRs include the toll-like receptors (TLRs) and 
the mannose receptor. Eleven TLRs have been identified thus far and differ based upon 
their cellular localization and the type of pathogen they recognize. For example, TLR2 
and TLR4 are found on the cell surface and detect bacterial lipoproteins and Gram-
negative lipopolysaccharide (LPS), respectively, whereas TLR9 is found within the cell 
and recognizes bacterial and viral DNA ([5], [14], [12]). The innate immune system can 
thus discriminate against the different types of pathogens to ensure that the appropriate 
adaptive immune response is generated.  
The adaptive immune response provides specialized defense and long-lasting 
immunity against a specific pathogen. Though the adaptive immune response is slower 
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(on the order of days to weeks), the immunological memory it provides allows for a 
stronger and quicker response upon future encounters with the pathogen [13].  Antigen-
presenting cells, namely dendritic cells (DCs), act as a bridge between the innate and the 
adaptive immune systems, stimulating the cells of the adaptive response that are 
responsible for the production of cellular and humoral immunological memory. The 
adaptive response itself is facilitated by B and T lymphocytes [5]. The process of antigen 
presentation and activation of T and B cells are discussed in the following sections. 
1.2.2 Dendritic Cells and Antigen Presentation 
Dendritic cells are considered to be the most effective antigen-presenting cells 
and are critical for the induction of the adaptive immune response ([15],[16], [17]). DCs 
are responsible for monitoring peripheral tissues for foreign antigen. Upon detection of 
foreign antigen, DCs internalize the antigen and travel to lymph nodes to present the 
antigen to T cells for induction of the adaptive response. Initially, dendritic cells are in an 
immature form when scanning the peripheral tissues and are highly endocytic in order to 
more efficiently internalize antigen [15]. Upon antigen uptake, the cells undergo a 
maturation process whereby their phenotype and function change. 
As DCs mature after antigen uptake, there is a decrease in their ability to 
internalize antigen and an increase in their ability to process and present antigen ([15], 
[5]). Antigen processing and presentation are crucial in the lymphoid tissue, where the 
DCs migrate following antigen capture. Mature DCs express major histocompatability 
complex (MHC) molecules, MHC-peptide complexes, and costimulatory molecules, 
which are necessary for antigen presentation and DC interaction with T cells [15]. Since 
DCs control the quality of the antigen-directed immune response, certain features affect 
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the maturation of dendritic cells to direct the type of immune response generated [15]. 
For example, TLR ligands give the dendritic cell information as to the nature (e.g. 
bacterial or viral) of the infecting pathogen ([5], [13]). This information transfer, in turn, 
allows the DC to activate the appropriate T cells and generate a more effective immune 
response.  
Following uptake, antigens undergo different processing and presentation 
depending on the nature of the antigen. For example, exogenously-produced antigens (i.e. 
soluble and particulate antigens) are degraded by endosomal proteases and loaded onto 
MHC class II molecules to be presented on the cell surface as a MHC class II:peptide 
complex ([5], [16]). This complex then proceeds to activate CD4
+
 T helper cells. On the 
other hand, intracellular antigen (i.e. cytosolic) is processed by cytosolic proteasomes and 
then transported to the endoplasmic reticulum via the transporter-associated protein 
(TAP) complex to be loaded onto MHC class I molecules ([5], [16]). It is subsequently 
presented on the DC surface as a MHC class I:peptide complex that can then activate 
CD8
+
 T cells. Exogenous antigens are not limited to MHC class II complexes: they can 
also be loaded onto MHC class I molecules and presented to CD8
+
 T cells by a process 
called cross-presentation. This occurs when exogenous antigens escape endosomes and 
are degraded by cytosolic proteasomes, or when the antigen is degraded in endosomes 
and exchanged with peptide loaded onto MHC class I molecules ([5], [16], [18]). 
Dendritic cells are well known for their ability to carry out either method of cross-
presentation [5].  
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1.2.3 T and B Lymphocytes 
Mature DCs are considered to be the most potent activators of naïve T cells. A 
single DC is capable of activating 100-1000 T cells [5]. Activation and clonal expansion 
of T cells by DCs requires two signals: the first signal comes from the stimulation of the 
T cell receptor and its co-receptor by the MHC:peptide surface complex, while the 
second signal comes from ligation of CD28 on T cells by B7 molecules (CD80 + CD86) 
on DCs ([5], [16]). 
Once activated, naïve CD4
+ 
and CD8
+
 T cells lead to different types of immune 
responses. The T cells are so named due to the expression of different costimulatory 
molecules on their surfaces: CD4
+ 
T cells express CD4, whereas CD8
+
 cells express CD8. 
It is CD8
+
 T cells that recognize antigen bound to MHC class I molecules. Since this 
antigen is generally of intracellular origin, CD8
+
 T cells are cytotoxic in function so as to 
eliminate cells infected with the intracellular pathogen ([5], [19]). Conversely, CD4
+ 
T 
cells recognize MHC class II-associated peptide from extracellular pathogens.  
The CD4
+ 
T cell response can be divided into two effector cells types: type 1 
(Th1) and type 2 (Th2) T helper cells ([5], [19]). These cells secrete different cytokines 
that help direct the immune response. Th1 cells are associated with IFN-γ, IL-12 and 
TNF-α, whereas cytokines for Th2 cells include IL-4, IL-5, IL-10 and IL-13 ([5], [20]). 
The Th1 response is a pro-inflammatory response and enhances cellular immunity [20]. 
On the other hand, the Th2 response involves the stimulation of B cells and the 
subsequent production of antibodies for targeting extracellular pathogens [20].   
B cells are responsible for the production of antibodies, i.e. humoral immunity. 
Pathogens are recognized by receptors on the surface of B cells in a very pathogen-
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specific manner. It is important to note that B cells recognize pathogenic protein in its 
native form [5]. When binding between the pathogen and a B cell receptor occurs, the B 
cell internalizes and processes the pathogen to present its epitopes in complex with MHC 
class II molecules on the cell surface [21]. A helper CD4
+ 
T cell with the ability to 
recognize the specific peptide being presented by the B cell can activate the B cell to 
produce antibodies against that pathogen ([5], [21]). The function of antibodies is to bind 
and neutralize toxins and eliminate whole pathogens (e.g. bacteria). Five different classes 
of antibodies exist: IgA, IgD, IgE, IgG, and IgM. IgG is most abundant in internal body 
fluids, such as the blood and lymph, while IgA is principally found at mucosal surfaces 
[21].  
The advantage of T and B lymphocyte activation is the formation of 
immunological memory. One result of the expansion of pathogen-specific T and B cells 
is the production of long-lived memory cells. Upon re-infection, these cells react much 
faster and more efficiently than naïve immune cells in eliminating the pathogen. This 
immunological memory is the goal of vaccination.  
1.3 New Generation Vaccines 
Vaccines function by delivering an antigen to the immune system in such a way 
so as to stimulate an antigen-specific, adaptive immune response for long-term protection 
against that antigen [22]. Many traditional vaccines consist of live attenuated pathogens, 
whole inactivated organisms, or inactivated bacterial toxins. These vaccines come with 
certain drawbacks, including safety concerns surrounding reactogenicity and, for some, a 
limitation to humoral immunity ([6], [23], [24]).  
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Recent advances have led to new vaccine approaches that are based on 
recombinant proteins or peptides. While they are advantageous in their reduced toxicity, 
these new vaccines are also poorly immunogenic on their own ([23], [4], [5]).  To 
improve their immunogenicity, new vaccines will require the aid of safe and effective 
adjuvants and antigen delivery systems to induce a more potent immune response ([23], 
[3]). 
1.4 Adjuvants and Antigen Delivery Systems 
Adjuvants are defined as agents that act in combination with antigens to enhance 
and direct the immune response against that antigen ([3], [23]). Adjuvants include 
mineral salts (e.g. aluminum and calcium compounds), immunostimulatory agents (e.g. 
TLR ligands), and particulate delivery systems (e.g. polymer particles) [23]. Adjuvants 
can function to (a) create an antigen depot for slow release of the antigen to the immune 
system, (b) deliver the antigen to APCs and improve antigen internalization, and (c) 
direct and enhance the immune response generated by the antigen [6]. The following 
sections provide a discussion of some of the main classes of adjuvants. 
1.4.1 Mineral Salt Adjuvants 
Aluminum salts, namely aluminum hydroxide and aluminum phosphate, are the 
most common of the mineral salt adjuvants. They have been used in many vaccines 
licensed for clinical use, including diphtheria toxoid, tetanus toxoid and acellular 
pertussis (DTaP) and hepatitis B ([25], [26]). Aluminum salts possess an adjuvant effect 
in their ability to (a) act as an antigen depot, (b) present a dense population of antigen to 
recognition receptors, and (c) be of sufficient size for phagocytosis by APCs [27]. 
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Limitations of aluminum salts include the potential formation of granulomas at the site of 
injection and the production of IgE-mediated allergic reactions ([22], [28]). In addition, 
the adjuvant is associated with humoral or Th2-type immune responses and, thus, is not 
as effective against intracellular pathogens, which require a cell-based immune response 
([3], [29]). 
Calcium phosphate has been studied as an alternative to aluminum adjuvants and 
has been used in childhood diphtheria-tetanus-pertussis vaccines ([22], [28]). Its 
properties are similar to those of the aluminum salts, though it does offer certain 
advantages. Calcium phosphate is a normal constituent of the body, therefore it is 
biocompatible and biodegradable [30]. In addition, calcium phosphate does not elicit the 
IgE response associated with aluminum adjuvants [26].  
1.4.2 Immunopotentiators 
This class of adjuvants activates immune cells through direct interaction with 
recognition receptors, such as the toll-like receptors, and has the ability to guide the 
immune response [3]. Immunopotentiators are typically pathogen-derived, such as 
monophosphoryl lipid A (MPLA) and CpG oligonucleotides. MPLA, a TLR4 agonist, is 
a safer derivative of gram-negative lipopolysaccharide (LPS) and has been approved for 
use in Europe and the US ([31], [32], [33]). CpG (cytosine–phosphate–guanine) is a 
common motif in bacterial and viral DNA and is recognized by TLR9 ([31], [32], [34]). 
MPLA and CpG are associated with enhancing Th1 and cell-based immune responses 
([35], [36]). Immunopotentiators may be combined along with other adjuvants for a 
greater immunogenic effect.  
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1.4.3 Particulate Delivery Systems 
Polymeric microparticles and nanoparticles have been studied as antigen delivery 
systems for many years. Particulate delivery systems offer many advantages, including 
(a) protecting antigen that may be susceptible to degradation upon injection, (b) 
controlled release of antigen to prolong its exposure to the immune system, (c) 
incorporation of immunostimulatory agents for added adjuvant effect, and (d) surface 
conjugation of antigen to present it in a similar manner as the pathogen ([19], [6], [32]). 
Perhaps the most widely studied polymer is PLGA, which is the focus of the remaining 
sections. 
1.5 Overview of PLGA  
PLGA has been studied for the purpose of drug delivery since the 1960s [37]. It is 
an aliphatic polyester composed of different ratios of L-lactic, D-lactic, and glycolic acid 
[17]. In an aqueous environment, PLGA is hydrolyzed into its acid monomers, which are 
then metabolized by the citric acid cycle [38]. Due to the biodegradable and 
biocompatible nature of the polymer, these particles present an excellent safety profile. 
Indeed, PLGA is used in numerous products are that approved for clinical use by both the 
US Food and Drug Administration (FDA) and the European Medical Agency (EMA) 
([39], [40]). PLGA presents a promising strategy for the purpose of vaccine delivery. 
1.5.1 Preparation of PLGA Particles 
There are three methods commonly used for encapsulating protein and peptide 
antigens into PLGA particles: the w/o/w double emulsion process, phase separation 
(coacervation), and spray drying (Figure 1) ([41],[42]). For the w/o/w technique, an 
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aqueous solution of antigen is added to PLGA dissolved in an organic solvent. The two 
solutions are vigorously mixed to form the first w/o emulsion. This primary emulsion is 
then added to an aqueous solution of emulsifier and mixed again to form the w/o/w 
emulsion. The secondary emulsion is then stirred in an aqueous bath (with or without 
surfactant) for multiple hours to allow for solvent evaporation, during which time the 
particles harden. After solvent evaporation, the particles can be collected by filtration or 
centrifugation. The w/o/w method is best used to encapsulate water-soluble drugs such as 
proteins and peptides [42].  
 Phase separation and spray drying also involve the formation of a w/o emulsion. 
For the phase separation method, an organic non-solvent is added to the polymer solution 
to induce phase separation and the formation of coacervate droplets, which encapsulate 
the protein or peptide [42]. Spray drying forms PLGA particles by atomizing the w/o 
emulsion into a stream of hot air; this induces rapid solvent evaporation ([41],[42]). Both 
methods can be successfully used to encapsulate peptide and protein antigens [42]. 
1.5.2 Controlled Antigen Release 
Protein is released from PLGA microspheres in three phases: an initial burst, 
diffusion controlled release, and then erosion controlled release [43]. Burst release is 
associated with the diffusion of protein at the outmost layers of the polymer ([43], [44]). 
The protein release then enters a lag phase as the polymer undergoes hydrolysis [45]. 
Degradation of the polymer occurs by bulk erosion. During bulk erosion, water enters 
into the polymer matrix faster than hydrolysis of the polymer chains [46]. Consequently, 
erosion occurs throughout the entire polymer matrix until a critical molecular weight is 
reached. At this point, the degradation products are small enough to be soluble in water. 
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This causes the formation of a porous network within the polymer structure, allowing for 
the release of encapsulated antigen through diffusion ([47], [48], [49]). During erosion-
controlled release, the polymer fully hydrolyzes, eventually leading to the end of protein 
release [45]. 
The rate of polymer erosion – and, consequently, the protein release profile – is 
influenced by the molecular weight, crystallinity, and hydrophobicity of the polymer 
([50], [51]). PLGA with a lower molecular weight and higher hydrophilicity will degrade 
more quickly. Glycolic acid, which has no methyl group on the α-carbon, is more 
hydrophilic than lactic acid. Hence, a higher ratio of glycolic acid will cause faster 
degradation with the absence of polymer crystallinity. Similarly, PLGA containing 
amorphous D,L-lactic acid degrades faster than polymer containing only crystalline L-
lactic acid owing to the inhibition of molecular movements and water entry into the 
polymer crystallites ([17], [45]). 
1.6 PLGA Particles as Antigen Delivery Systems 
It has been well established that PLGA particulates with adsorbed or encapsulated 
antigen provide an enhanced immune response relative to the soluble antigen alone. 
Advantages to using PLGA particulates include targeting of particulates for uptake by 
APCs, incorporating immunostimulators into the delivery system, and controlled release 
of antigen ([41], [3], [52]).  
1.6.1 Uptake of PLGA Particles by APCs 
As activators of the adaptive immune system, APCs are important targets for 
vaccines. PLGA particulates can be modified in their design to enhance their 
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internalization by APCs. A key factor in facilitating internalization is particle size. 
Particle sizes typically fall into the following three ranges: (1) 10-100 μm for antigen 
depots, (2) 0.5-10 μm for delivery to APCs, and (3) 50-500 nm for delivery to APCs and 
circulation in the blood ([53], [54]). Many studies have shown that PLGA particulates of 
a size less than 10 μm are preferentially internalized by APCs ([55], [17], [56], [52], [57], 
[6], [58], [59]). APCs internalize particles by endocytosis, with particles smaller than 0.5 
μm being taken up by receptor-mediated endocytosis and particles larger than 0.5 μm 
being internalized by both receptor-mediated and receptor-independent endocytosis 
(including phagocytosis and macropinocytosis) [60]. 
To further facilitate uptake, the particle surface can be decorated with ligands that 
bind to receptors found on the surface of APCs. Dendritic cells, which are the most 
potent of APCs, express different surface receptors, such as the mannose receptor, DC-
SIGN, and DEC-205. Particles affixed with ligands of these receptors (e.g. a ligand with 
a terminal mannose) or antibodies against these receptors (e.g. an anti-DEC-205 
antibody) can enhance the specificity of the particles for APCs and improve their 
internalization through receptor-mediated endocytosis ([53], [17]). 
1.6.2 Incorporation of Immunostimulators 
Co-delivery of immunostimulators with an antigen in PLGA particulates enables a 
guided and more robust antigen-directed immune response to develop. Oral vaccination 
of mice with particles containing ovalbumin and MPLA resulted in both a stronger IgG 
and IgA response compared to soluble ovalbumin and ovalbumin encapsulated without 
MPLA [61]. Subcutaneous vaccination of mice with PLGA nanoparticles containing the 
melanoma antigen tyrosinase-related protein 2 (TRP2) and the TLR4 ligand 7-acyl lipid 
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A induced a CD8
+
 T cell response against the antigen. This T cell response was stronger 
compared to that produced by soluble antigen alone [62].  Mice vaccinated with tetanus 
toxoid co-encapsulated with CpG ODN in PLGA nanoparticles were found to produce 
both a Th1 and Th2 type response, with a bias towards Th1 [36]. 
Due to the controlled-release nature of PLGA particles, delivery of TLR ligands 
by this delivery system limits the amount of TLR ligand released systemically. This is 
beneficial due to the non-specific immune activity and toxicity that may otherwise 
develop. In addition, PLGA particulates allow for the simultaneous delivery of multiple 
TLR ligands, which opens up more possibilities for directing the immune response. 
1.7 Limitations of PLGA Particulate Vaccines  
Though a promising vaccine delivery system, PLGA particulates do possess 
certain limitations. Two limitations that will be discussed here are cost and antigen 
instability.  
1.7.1 Cost  
Advancement of a PLGA antigen delivery system into the clinic could be 
prevented if production costs for the delivery system are too high. Acceptable cost is 
dependent upon the vaccine at hand – for example, the acceptable cost for a cancer 
vaccine may be much higher than that for a routine childhood immunization. Currently, 
cost is a significant issue when developing PLGA delivery systems, in particular because 
most microencapsulation methods require aseptic manufacturing conditions ([63], [64]). 
This adds significant cost, particularly for the aseptic processing of organic solvents [9].  
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1.7.2 Antigen Instability  
Release of stable antigen from PLGA particles has proven to be a challenge to the 
field. Ideally, released antigen will have an intact primary and three-dimensional 
structure where linear and conformational epitopes are to be found. However, instability 
can occur at a number of stages, including during encapsulation of the antigen, 
lyophilization, storage of the protein-loaded microspheres, and antigen release [8]. 
During traditional encapsulation methods, forces from emulsification, exposure to water-
oil interfaces, and elevated temperatures can denature proteins ([8],[9]). Further, without 
the addition of stabilizing agents, conditions during lyophilization and storage can also 
cause the antigen to lose its native structure [11]. Instability most commonly takes the 
form of aggregation (covalent and non-covalent), protein unfolding, and hydrolysis of the 
peptide backbone ([10], [11]). During release, water content in the polymer and the 
microclimate pH in the polymer pores affect the antigen stability. Increasing water 
content makes the protein more flexible and, hence, prone to destabilization [11]. As acid 
byproducts are produced during polymer hydrolysis, the microclimate pH is lowered and 
may lead to protein denaturation [11].  All of these factors make it difficult to deliver 
protein with its antigenicity unaffected.  
1.8 Overcoming the Limitations: Active Self-Microencapsulation 
One way to overcome both high cost and antigen instability is to employ simpler 
methods for encapsulating antigen into the PLGA carrier. One such method is the active 
self-microencapsulation paradigm described by the Schwendeman laboratory. The 
potential advantages of this method include reduced manufacturing costs and improved 
stability of encapsulated proteins ([11],[9], [8])  
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Active self-microencapsulation relies on the ability of the polymer to self-heal at 
higher temperatures in aqueous media. PLGA particles are first made by the w/o/w 
method without the addition of protein (i.e. “blank” particles). Trehalose is included in 
the formulation as a porosigen to help create a porous network within the particles. The 
osmotic pressure created by the trehalose causes an influx of water through the polymer 
phase and into any accessible pores. In response to this stress, the polymer swells and 
new, interconnected pores form to relieve the pressure. Incorporated into the formulation 
is a protein-trapping agent, such as an aluminum or calcium salt adjuvant, which is 
accessible through the pore network. Once the blank particles have been prepared, they 
can be lyophilized and stored for later use (provided necessary lyoprotective measures are 
taken). Additionally, at this stage, the blank particles can undergo sterilization (Figure 2). 
To load antigen, the particles are simply incubated in an aqueous solution of the 
protein. The mixture is initially incubated at a temperature much lower than the glass 
transition temperature (Tg) of the polymer. This step allows the protein to enter through 
the open pores of the particles and bind to the protein-trapping agent for improved 
loading [8]. Next, the mixture is incubated at a temperature higher than the Tg. When a 
polymer is at a temperature above its Tg, the polymer chains become mobile and 
rearrange ([11],[9], [8]). It is at this step that self-healing of the polymer occurs and the 
pores close (i.e. heal). The result is protein loaded within the particles (Figure 3). 
Due to the nature of active self-microencapsulation, peptide and proteins 
encapsulated by this method encounter fewer sources of destabilization. The protein does 
not encounter the detrimental micronization forces or the water-oil interfaces of 
encapsulation. The protein also avoids destabilization due to lyophilization conditions 
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since the blank particles are lyophilized before the addition of antigen. This encapsulation 
paradigm also simplifies sterilization of the product. Sterilization has been a challenge 
due to the denaturing effect it can have on antigen encapsulated in particles. However, by 
this novel method, the blank particles can be sterilized before the introduction of the 
antigen ([11], [9], [65]). In addition, it is expected that the protein-trapping agent 
improves protein stability by immobilizing the antigen, making it less prone to unfolding 
and aggregation. Thus, active self- microencapsulation is a promising approach for 
antigen encapsulation, particularly for maintaining the stability and immunogenicity of 
proteins.  
1.9 Hypothesis and Thesis Objectives 
PLGA particles are a promising delivery system for the development of new 
generation vaccines, particularly for poorly immunogenic protein and peptide antigens. 
The self-encapsulation method has demonstrated potential of overcoming certain 
limitations of traditional PLGA particles, namely antigen instability.  It is hypothesized in 
this thesis that, by employing active self-encapsulation of antigen in calcium 
phosphate/PLGA microspheres of a size range suitable for targeting antigen-presenting 
cells, the resulting vaccine will have improved antigen stability and immunogenicity 
relative to both traditional PLGA microspheres and free calcium adjuvant. The purpose 
of this thesis is to test this hypothesis. The following chapters discuss the investigation of 
a self-encapsulating PLGA microsphere formulation for delivery of antigen to APCs and 
the type of immune response generated after subcutaneous and intranasal administration. 
It is noted that while three separate investigations are described here (formulation 
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characterization, in vitro cell studies, and in vivo immunization studies), they were 
combined in a two-chapter format for publication purposes.  
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1.10 Figures 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-1. Diagram of common microencapsulation techniques: solvent evaporation, 
phase separation, and spray drying. Adapted from [41]. 
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Figure 1-2. Comparison of the self-encapsulation process to traditional encapsulation. 
Unlike traditional methods, self-encapsulation offers the ability to sterilize the 
microspheres prior to antigen loading. Adapted from [11]. 
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Figure 1-3. Diagram of the stages of self-encapsulation. Porous microspheres (inset A), with an internal protein-trapping agent 
(aluminum or calcium phosphate adjuvant), are mixed in an aqueous solution of antigen under mild agitation. This mixture is initially 
incubated at lower temperatures for active loading to take place. During this step, the antigen diffuses into the polymer pores and sorbs 
to the protein-trapping agent. The mixture is then heated at a temperature above the glass-transition temperature of the polymer for the 
pores to heal (close), thereby encapsulating the antigen within the microspheres (inset B). Adapted from ([8], [9]). 
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Chapter 2 
Development and Characterization of Self-Encapsulating 
PLGA Microspheres for Vaccine Delivery 
2.1 Abstract 
Conventional preparation methods for microspheres of poly(lactic-co-glycolic 
acid) (PLGA) generally subject the antigen to destabilizing conditions, including organic 
solvent and shear stresses. Recently, we developed a technique, termed “self-
encapsulation,” for the loading of large molecules into pre-made, porous PLGA 
microspheres. By applying this loading method, the antigen can better maintain its 
bioactivity and immunoreactivity since it bypasses many of the denaturing conditions of 
conventional techniques. In this study, we further expand upon this approach by 
developing a formulation of self-encapsulating (SE) microspheres for vaccine delivery. 
The formulation was characterized, and an intranasal immunization study was performed 
in mice to investigate the immune response generated by the microspheres. CaHPO4 
adjuvant gel was incorporated into the microspheres as a protein-trapping agent for 
improved encapsulation efficiency. The formulation demonstrated continuous release of 
OVA model antigen over a 49-day period. Released OVA maintained its antigenicity 
over the first 21 days of release, confirming the stability of the aqueous SE method. Mice 
were immunized intranasally with prime and booster doses of OVA (10 µg), loaded into 
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microspheres or co-administered with cholera toxin B (CTB) mucosal adjuvant. 
Microspheres generated a Th2-type response in both serum and local mucosa, with IgG 
antibody responses approaching those generated by CTB. This formulation of self-
encapsulating microspheres shows promise for further study as a vaccine delivery system.   
2.2 Introduction 
Vaccination is one of the most successful public health interventions, as 
evidenced by the eradication of smallpox and polio, which is approaching eradication. 
Despite these successes, there is still much room for improving vaccine coverage and 
efficacy. One major challenge to vaccine coverage is that many vaccines require multiple 
immunizations for protective immunity ([1], [2]). Non-compliance with vaccination 
programs can reach 70% in some developing countries, meaning that a large part of the 
population is under-immunized ([1], [2]). In addition, new generation vaccines will have 
quite a challenge inducing potent immunity considering poorly immunogenic antigens 
and complex vaccine targets [3].     
Understanding these difficulties has led to the development of novel approaches 
to vaccine delivery, with the goal of improving vaccine performance [4]. Antigen 
delivery systems (e.g. microspheres, nanoparticles, and liposomes) and adjuvants (e.g. 
aluminum and calcium compounds) have been widely explored as approaches to improve 
the immune response generated by the antigen. This is especially true for subunit- and 
recombinant protein antigens, which are generally poorly immunogenic on their own due 
to difficulty activating antigen-presenting cells and their short in vivo half-life ([5], [6]). 
Adjuvants and delivery systems may improve antibody- and cell-mediated immunity, 
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decrease the amount of antigen required in a dose, and decrease the number of doses 
necessary for immunization, among other benefits [4].  
Polymeric microspheres and nanoparticles have been widely researched for their 
use as vaccine delivery systems. One of the most commonly used polymers for this 
application is poly(lactic-co-glycolic acid) (PLGA) ([5], [1]). PLGA particles have been 
of interest due to their biodegradable and biocompatible nature and their proven safety 
record in humans [7]. Depending on polymer molecular weight and the ratio of lactic to 
glycolic acid components, the release of antigen from PLGA particles can occur over a 
few days or be sustained for over a year [8]. In addition, studies performed with PLGA 
microspheres have demonstrated their capacity to induce both antibody- and cell-
mediated immune responses in mice [9].  
Despite the benefits of PLGA particles, there are a number of challenges facing 
the development of this delivery system. One of the key challenges is antigen instability, 
which can occur during microsphere production, lyophilization and storage of the 
microspheres, and during antigen release ([10], [7]). Traditional microsphere production 
methods expose the antigen to detrimental conditions, which include forces from 
emulsification procedures and exposure to aqueous/organic solvent interfaces ([10],[11]). 
Protein instability takes such forms as aggregation and structural unfolding and can result 
in a significant loss of protein antigenicity ([12], [13]).  
In an effort to improve protein stability in PLGA particles, our group has 
developed an encapsulation paradigm, termed “self-encapsulation,” that bypasses many 
of the challenges of traditional PLGA encapsulation techniques ([10], [11]). This method 
relies on the ability of polymer surface pores to heal (close) at temperatures above the 
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glass transition temperature (Tg) of the polymer [14]. The self-encapsulating 
microspheres contain an interconnecting pore network and an inner protein-trapping 
agent, such as an aluminum- or calcium-based adjuvant gel, that is accessible through the 
pores. Through simple mixing of the microspheres in an aqueous solution of antigen, the 
antigen diffuses into the pores and binds to the trapping agent. Subsequent heating of the 
system above the Tg results in pore healing and closure of loaded protein within the 
microsphere. Due to its gentle processing conditions, self-encapsulation is a promising 
approach for maintaining the antigenicity of encapsulated antigen. 
In this work, we investigate the application of self-healing microencapsulation to 
the delivery of vaccine antigens. Herein, we describe the development and 
characterization of a formulation of self-encapsulating microspheres for antigen delivery. 
Formulation characteristics were studied, including the (1) incorporation of protein-
trapping agent (CaHPO4 adjuvant gel), (2) encapsulation of ovalbumin model antigen, (3) 
release kinetics, and (4) stability and antigenicity of released ovalbumin. The formulation 
was then tested in an intranasal immunization study in mice to explore the type and 
quality of the immune response generated.  
2.3 Materials and Methods  
2.3.1 Materials 
PLGA 50:50 (i. v. = 0.60 dL/g, Mw = 53.4 kDa, ester terminated) was purchased 
from Lactel (Durect Corporation, USA). Poly(vinyl alcohol) (PVA) (88% hydrolyzed, 
Mw = 25 kDa) was purchased from Polysciences Inc. (USA). Alexa Fluor 647-OVA was 
purchased from Molecular Probes (Thermo Fisher Scientific Inc., USA). Cholera toxin B 
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subunit, ovalbumin grade V, and rhodamine 6G were purchased from Sigma (USA). 
Endofit OVA for immunization studies was purchased from Invivogen (USA). 
Biotinylated goat anti-mouse IgG, IgG1, IgG2C, and IgA were purchased from Southern 
Biotech (USA). RPMI 1640 medium, heat-inactivated FBS, L-glutamine, 
penicillin/streptomycin, 2-mercaptoethanol, and ACK lysis buffer were purchased from 
Invitrogen (Thermo Fisher Scientific Inc., USA). PMA/ionomycin (Cell Stimulation 
Cocktail) was purchased from eBioscience (USA). All other reagents and solvents 
purchased from commercial suppliers and were of analytical grade or higher.  
2.3.2 Preparation of CaHPO4 Adjuvant Gel 
CaHPO4 adjuvant gel was prepared as described in [15]. Equal parts Na2HPO4 
and CaCl2
 
were rapidly mixed together, and the pH immediately adjusted to 6.8-7.0 with 
NaOH. The resulting precipitate was washed 5 times with sterile 0.9% NaCl to remove 
excess phosphate and then resuspended in 0.9% NaCl to the desired concentration.  
2.3.3 Preparation of Self-Encapsulating PLGA Microspheres 
Porous, self-encapsulating PLGA microspheres were prepared by the w/o/w 
double emulsion-solvent evaporation technique. Calcium phosphate adjuvant gel 
(CaHPO4) was included as a protein-trapping agent and trehalose as a porosigen. The 
inner water phase contained calcium phosphate gel (28 mg/mL) and trehalose (28 
mg/mL) in 25 mM succinate buffer (pH 4.0). One hundred microliters of inner water 
phase was added to 1 mL of 50 mg/mL PLGA in methylene chloride. The mixture was 
sonicated at 50% amplitude for 1 minute using a Sonics Vibra-Cell VC130 Ultrasonic 
Processor (Sonics & Materials Inc., USA) to form the first emulsion. Four milliliters of 
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5% (w/v) PVA solution (used as an emulsion stabilizer) was added to the primary w/o 
emulsion, and the mixture was vortexed (Genie 2, Scientific Industries Inc., USA) for 30 
seconds to produce the w/o/w double emulsion. The w/o/w emulsion was poured into 100 
mL of chilled 0.5% (w/v) PVA under rapid stirring and hardened at room temperature for 
6 hours. Microspheres were passed through a 10-µm mesh sieve, and the filtrate was 
collected and centrifuged (7000 rpm for 5 minutes). The microspheres in the pellet were 
washed repeatedly with double-distilled (dd) H2O and then lyophilized (FreeZone 2.5, 
Labconco, USA).  
2.3.4 Determination of CaHPO4 Loading by ICP-OES  
Loading of CaHPO4 in PLGA microspheres was determined by inductively 
coupled plasma-optical emission spectrometry (ICP-OES). Briefly, approximately 10 mg 
of microspheres were added to 1 mL acetone, vortexed, and then centrifuged at 7000 rpm 
for 5 minutes. The supernatant polymer solution was removed and the pellet was washed 
twice more with 1 mL acetone. The resulting residue was dried in a fume hood to allow 
for evaporation of the acetone. One milliliter of 30% HCl was added to each sample to 
dissolve the residue. The samples were then diluted with ddH2O to bring the theoretical 
concentration of Ca ion in the samples to between 1 and 15 ppm. The concentration of Ca 
ion was then analyzed by ICP-OES (Perkin-Elmer Optima 2000 DV with Winlab 
software). Each sample was measured three times and analysis was done in triplicate.  
2.3.5 Distribution of CaHPO4 Gel within Microspheres 
To view the distribution of CaHPO4 gel within the particles after microsphere 
preparation, the gel was first made fluorescent by pre-loading it with a fluorescent 
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ovalbumin conjugate. CaHPO4 gel was incubated with an Alexa Fluor 647-OVA 
conjugate at a ratio to meet the capacity of the gel for the OVA. The mixture was 
incubated at 37°C for 2 hours under mild agitation on a table-top shaker. Following 
loading of the protein onto the gel, the gel was then used in the inner water phase for 
microsphere preparation. Fluorophore-loaded PLGA microparticles were produced by 
encapsulating Rhodamine 6G in the oil phase. Lyophilized microspheres were 
resuspended in ddH2O and placed on a glass side and covered with a coverslip. The 
sample was viewed using a Nikon A-1 spectral confocal microscope with NIS Elements 
software (Nikon Instruments).  
2.3.6 Scanning Electron Microscopy  
The surface morphology of microspheres was examined using a Hitachi S3200N 
scanning electron microscope (SEM) (Hitachi, Japan). Briefly, lyophilized microspheres 
were fixed on a brass stub using double-sided carbon adhesive tape. The sample was 
made electrically conductive by coating with a thin layer of gold for 120 seconds at 40 W 
under vacuum. Images were taken at an excitation voltage of 8.0 kV. EDAX® software 
was used to obtain the final image.  
2.3.7 Microsphere Size and Zeta Potential Analysis 
The volume median diameter of the microspheres was measured using a 
Mastersizer 2000 (Malvern Instruments Ltd, UK). Ten milligrams of lyophilized 
microspheres were suspended in 5 mL 0.5% PVA solution and briefly vortexed. Six 
measurements were performed per sample at a stir speed of 2000 rpm and sampling time 
of 15 seconds. Zeta potential was measured with a Zetasizer Nano ZSP (Malvern 
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Instruments Ltd, UK). Lyophilized microspheres were suspended in ddH2O (0.1% mass) 
and placed in a disposable folded capillary zeta cell (Malvern Instruments Ltd, UK). Each 
sample was measured six times.  
2.3.8 Active Self-Encapsulation of Ovalbumin by PLGA Microspheres 
Active encapsulation of ovalbumin (OVA) by PLGA microspheres was carried 
out in two phases: an initial incubation of the porous microspheres in protein solution at a 
temperature below the polymer Tg for protein sorption onto the CaHPO4 gel, and then 
incubation at a temperature above the Tg for the polymer pores to heal. Briefly, 
approximately 20 mg of lyophilized microspheres were incubated in an OVA solution 
(0.5 mg/mL OVA in 0.4 mL 10 mM MOPS buffer, pH 7.4) at 4°C for 24 hours and then 
25°C for 24 hours (T<Tg), followed by incubation at 42°C for 48 hours (T>Tg). 
Incubation was performed under constant agitation using a rigged rotator (Glas-Col, 
USA).  
2.3.9 Determination of Protein Loading and Encapsulation Efficiency 
After self-encapsulation of the protein, the microsphere samples were centrifuged 
at 7000 rpm for 5 minutes. The supernatant was passed through a low protein-binding 
Durapore (PVDF) membrane-based syringe filter unit (Millipore Corporation, USA) and 
the filtrate collected. The microspheres were then washed once with ddH2O and the rinse 
filtered and collected. A modified Bradford assay was used to determine OVA 
concentration in the filtrates. Coomassie Plus® reagent (Thermo Fisher Scientific, USA) 
was added to the appropriate volume of standard OVA solution or filtrate sample in a 96-
well plate (Nunc, Thermo Scientific, USA). After 10 minutes, the absorbance was read at 
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595 nm using a Dynex II MRX microplate reader (Dynex Technology Inc., USA). The 
mass of OVA encapsulated by the microspheres was calculated by subtracting the mass 
of OVA in the filtrates from the mass of OVA in the initial loading solution. Percent w/w 
loading and encapsulation efficiency (EE) were quantified with the following formulas:  
 
% w w⁄ loading: 
mass of OVA encapsulated by the microspheres
mass of microspheres in loading sample + 
mass of OVA encapsulated
×  100 
 
% EE: 
mass of OVA encapsulated by the microspheres
mass of OVA in initial loading solution
×  100 
 
2.3.10 Capacity of Unencapsulated CaHPO4 Gel for Ovalbumin 
To determine the capacity of unencapsulated CaHPO4 gel for OVA, 1 mg of gel 
was incubated with 200 µg OVA (0.5 mg/mL in 10 mM MOPS buffer, pH 7.4) at 25°C 
for 24 hours under mild agitation. Following incubation, the mixture was centrifuged at 
7000 rpm for 5 minutes. The mass of OVA remaining in the supernatant was determined 
using a modified Bradford assay. Based upon the mass of OVA in the original loading 
solution and the mass of OVA in the supernatant, the amount of OVA loaded onto the gel 
was calculated. The capacity of the gel for OVA was determined by taking the ratio of 
OVA loaded and the mass of gel present in the loading mixture. 
2.3.11 Distribution of Encapsulated Ovalbumin within Microspheres 
To observe the distribution of self-encapsulated OVA within microspheres, 
fluorescently-labeled OVA was loaded into microspheres containing a rhodamine dye in 
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the polymer phase and observed by confocal microscopy. Briefly, rhodamine 6G was 
added to the oil phase during microsphere production to dye the polymer. The 
microspheres were then used to load Alexa Fluor 647-OVA using the above self-
encapsulation process. Directly following encapsulation, the loaded microspheres were 
centrifuged at 7000 rpm for 5 minutes and the supernatant removed. Next, the 
microspheres were rinsed once with ddH2O. Following centrifugation and removal of the 
supernatant, the microspheres were resuspended in ddH2O and placed on a glass side and 
covered with a coverslip. The sample was viewed using a Nikon A-1 spectral confocal 
microscope with NIS Elements software (Nikon Instruments).  
2.3.12 Size Exclusion-High Performance Liquid Chromatography of Ovalbumin  
Size exclusion-high performance liquid chromatography (SE-HPLC) was 
performed using a TSKgel G3000SWxl column (Tosoh Bioscience, USA) on a Waters 
HPLC system (Waters, USA). The mobile phase consisted of PBS, pH 7.4, at a flow rate 
of 0.7 mL/min and injection volume of 50 µL. Protein detection by UV was done at 210 
and 280 nm.  
2.3.13 Evaluation of Ovalbumin Stability During Self-Encapsulation  
Ovalbumin stability in the conditions for self-encapsulation was investigated by 
incubating OVA solutions at the different temperatures required for the encapsulation 
process. OVA solutions (0.5 mg/mL) in 10 mM MOPS buffer, pH 7.4, were incubated 
under mild agitation on a rotator. One sample each was incubated at 4°C for 24 hours, 
25°C for 24 hours, 42°C for 48 hours, and 4°C for 24 hours + 25°C for 24 hours + 42°C 
for 48 hours. A separate sample was incubated at 80°C for 24 hours to induce 
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denaturation. The samples were then analyzed by SE-HPLC to examine OVA 
aggregation. 
2.3.14 In Vitro Release of Ovalbumin from Self-Encapsulating Microspheres 
Approximately 20 mg of OVA-encapsulated microspheres were incubated in 0.5 
mL PBS, pH 7.4, at 37 °C under constant agitation (240 rpm/min). At different 
incubation times (1, 3, 5, and 7 days, and then every 7 days until day 49), the mixture was 
centrifuged at 7000 rpm for 5 minutes and the supernatant was collected through a low 
protein-binding Durapore (PVDF) membrane-based syringe filter unit (Millipore 
Corporation, USA). Fresh release media (0.5 mL) was then added to the sample and the 
microspheres were resuspended to continue the release study. The OVA content in the 
supernatants was analyzed by SE-HPLC.  
2.3.15 ELISA for Quantifying Release of Antigenic Ovalbumin 
In vitro release samples collected and analyzed by SE-HPLC, as described above, 
were further analyzed by enzyme-linked immunosorbent assay (ELISA) to quantify the 
amount of antigenic OVA in each sample. Samples were collected at time points of 1, 3, 
5, 7, 14, and 21 days. Antigenic OVA was detected using a commercial chicken egg 
ovalbumin ELISA kit (Alpha Diagnostic International, USA), which was used according 
to the manufacturer’s instructions. Samples were diluted with the sample diluent provided 
with the kit to fall within the working range of the assay and then assayed in duplicate. 
The dilution was based upon the calculated concentration of OVA in the samples 
determined by SE-HPLC. The ELISA plate was read at 405 nm using a Synergy Neo 
plate reader with Gen5 software (Biotek Instruments Inc, USA).  
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2.3.16 Extraction of Unreleased Protein 
At the end of release, microspheres were dissolved in acetone (3 washes at 1 mL 
acetone per wash) to remove the polymer. The CaHPO4 gel and OVA pellet was allowed 
to dry in a fume hood before re-suspension in 1 mL 10% w/v sodium citrate to elute 
soluble OVA from the gel. The samples were analyzed by SE-HPLC to determine 
remaining soluble OVA. The residue was then dissolved in 0.1 mL of a denaturing (6 M 
urea, 1 mM EDTA) plus reducing agent (10 mM dithiothreitol) to dissolve any 
noncovalent and disulfide-bonded aggregates, respectively. The aggregated OVA was 
quantified using a modified Bradford assay as previously described. 
2.3.17 Immunization Study 
Female C57BL/6 mice, 6-7 weeks old, were purchased from Harlan Laboratories, 
Inc. and handled according the University of Michigan Institutional Animal Care 
guidelines. Mice (10 mice per group) were immunized intranasally (i.n.) with 15 µL 
(~7.5 µL per nare) of sterile PBS, cholera toxin B (CTB) co-administered with OVA (10 
µg CTB + 10 µg OVA), or microspheres loaded with OVA (10 µg OVA). A booster dose 
was given three weeks later on day 21 after primary immunization. On days 20 and 41, 
blood samples were collected by submandibular bleed for analysis of serum antibody 
titers. Blood was collected into Microvette 500 Z-Gel serum collection tubes (Sarstedt, 
Germany) and centrifuged at 10,000 x g for 5 minutes to separate the serum. Serum was 
stored at -80°C until analysis. 
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2.3.18 Bronchial Alveolar Lavage 
Mice were euthanized on day 42 and bronchial alveolar lavage (BAL) was 
performed for analysis of mucosal antibody titers. Briefly, the trachea were cannulated 
and lavage was carried out with approximately 0.75 mL of PBS. The bronchial alveolar 
lavage fluid (BALF) was centrifuged and the supernatant collected and stored at -80°C 
until analysis with ELISA. 
2.3.19 Measurement of Antibody Titers 
Serum and BALF samples were sent to the Immunology Core at the University of 
Michigan Cancer Center for ELISA analysis. The assays were performed using a 
standard ELISA protocol.  Briefly, OVA (10 µg/mL in carbonate/bicarbonate buffer) was 
used to coat 384-well plates overnight at 4°C.  Plates were washed and residual binding 
sites blocked with 0.2% casein in Tris-buffered saline (TBS) for at least one hour.  The 
same buffer was used for sample dilutions. Ig detection antibodies were minimally 
diluted to the manufacturer’s suggested working range. IgG, IgG1, and IgG2C response 
was measured for both serum and BALF samples, while IgA response was also included 
for BALF. 
2.3.20 Cytokine Response 
On day 42, mouse spleens were collected under sterile conditions. Splenocytes 
were isolated by gentle disruption of the spleen through a mesh filter, and red blood cells 
were lysed with ACK lysis buffer and washed. Cells were plated at 5 x 10
5
 cells/well in a 
96-well tissue culture plate (Corning Inc., USA) with RPMI 1640 medium supplemented 
with 10% heat-inactivated FBS, 2 mM L-glutamine, 100 U/mL penicillin, 100 µg/mL 
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streptomycin, and 55 µM 2-mercaptoethanol. Cells were tested in duplicate and treated 
with medium (negative control), 2 µL/mL PMA/ionomycin (positive control), 25 µg/mL 
whole OVA, or 2 µg/mL OVA MHC class I or class II peptide. After 96 hours of 
incubation (37°C, 5% CO2), the well supernatants were collected and stored at -80°C 
until analysis. Samples were submitted to the Immunology Core at the University of 
Michigan Cancer Center for ELISA analysis of cytokine response. 
2.3.21 Statistical Analysis 
Statistical analyses were carried out using GraphPad Prism 6.0g software. Two-
way ANOVA with Bonferroni’s post-test was used to compare multiple groups. Values 
are reported as mean ± SEM (standard error of the mean).  
2.4 Results and Discussion 
2.4.1 Preparation and Characterization of Self-Encapsulating Microspheres 
Self-encapsulating PLGA microspheres were prepared by a standard double 
emulsion-solvent evaporation technique. Trehalose was added to the inner water phase to 
act as a porosigen to create the interconnected pore network in the microspheres. This 
pore network is necessary for the protein in the loading solution to diffuse through the 
pores into the microspheres during self-encapsulation [11]. As shown in Figure 1(a), 
scanning electron microscopy was used to verify that the formulation produced particles 
that displayed a spherical morphology and were porous in nature.  
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2.4.1.1 Incorporation of CaHPO4 Adjuvant Gel 
Calcium phosphate (CaHPO4) adjuvant gel was present in the inner water phase to 
be incorporated into the microspheres. The purpose of the gel was to act as a protein-
trapping agent within the microsphere pores. In previous work done by our lab, use of a 
protein-trapping agent, such as Al(OH)3 or CaHPO4 adjuvant gels, improved the 
encapsulation efficiency of the self-encapsulating microspheres compared to 
microspheres without an inner trapping agent ([11], [10]). To distinguish the two 
strategies, use of a protein-trapping agent is termed “active” self-encapsulation.  
Calcium phosphate adjuvant was selected as the protein-trapping agent in this 
study. Calcium phosphate is an alternative to the aluminum-based adjuvants. It is well-
tolerated and readily resorbed, being a natural constituent of the body [15]. CaHPO4 has 
been used in France for many years as an adjuvant with diphtheria-tetanus-pertussis 
(DTP) vaccines [16]. Unlike aluminum adjuvants, calcium phosphate does not lead to 
enhanced IgE production in animals and humans [15]. The adjuvant is thought to act as 
an antigen depot and improve uptake of the antigen by antigen-presenting cells (APCs) 
([1], [17], [15]).  
The CaHPO4 gel was prepared by rapid mixing (<10 seconds) of equimolar 
solutions of disodium hydrogen phosphate and calcium chloride, as described by Gupta et 
al. [15]. Gel prepared by rapid mixing was found to have much better adsorption of 
diphtheria toxoid compared to gel made by slower mixing (10 minutes) [15]. The 
adjuvant was then washed thoroughly with 0.9% sodium chloride to remove excess 
phosphate ions that would interfere with antigen adsorption.  
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Successful incorporation of the adjuvant in the microspheres was confirmed by 
ICP-OES (Table 1). In addition to measurement of the % w/w loading of the adjuvant 
(2.2 ± 0.1%), the distribution of the gel within the microspheres was viewed by confocal 
microscopy (Figure 2a). The CaHPO4 gel loaded with Alexa Fluor 488-ovalbumin was 
used in the inner water phase to be incorporated into microspheres. The gel was observed 
to be loaded within both smaller and larger microspheres and to be homogeneously 
distributed.  
2.4.1.2 Microsphere Size and Zeta Potential 
The formulation parameters were designed to produce microspheres of a size 
range smaller than 10 µm. In particular, sonication was used to form the primary 
emulsion since greater agitation is known to generate smaller particles [18]. A smaller 
microsphere size was desired for improved immune response as research has shown that 
particles smaller than 10 µm are preferentially phagocytosed by APCs compared to larger 
particles, with smaller particles eliciting a stronger immune response ([19], [20], [21], 
[22], [23]). The median microsphere diameter was found to be within the desired size 
range (7.05 ± 0.31 µm), with a zeta potential of -21.9 ± 2.1 mV (Table 1). 
Based upon their size, microspheres may carry out a number of functions. For 
example, microspheres can (1) act as a depot for continued release of antigen, prolonging 
exposure of the immune system to the antigen; and (2) facilitate uptake of the antigen by 
APCs, improving delivery of the antigen to the lymphoid organs [24]. Consequently, 
microsphere size is an important consideration for antigen delivery. 
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2.4.2 Self-Encapsulation of Ovalbumin Model Antigen 
Ovalbumin was loaded into microspheres by the active self-encapsulation process. 
Lyophilized microspheres were initially incubated in a solution of ovalbumin at lower 
temperatures, with mild mixing, to allow the protein to diffuse through the pores and sorb 
onto the CaHPO4 gel. Following this stage, the mixture was then incubated at a 
temperature above the Tg of the polymer in order for the microsphere pores to heal, 
thereby trapping the antigen within the particle. SEM was used to verify pore closure 
after self-encapsulation (Figure 1b). 
Results of the self-encapsulation are shown in Table 2. The mass of ovalbumin 
loaded into the microspheres was assessed by measuring the mass loss from the original 
loading solution. The measured % w/w loading of ovalbumin was found to be 0.60 ± 
0.05%. By comparing the ovalbumin capacity of the microspheres to that of the 
unencapsulated CaHPO4 gel (Table 2), it suggests that incorporation of the gel within the 
microspheres did not adversely affect the ability of the gel to sorb the protein. CaHPO4 
may adsorb antigen by electrostatic interaction, hydrophobic interaction, and ligand 
exchange [17]. The latter occurs by exchange of hydroxyl groups in the gel with 
phosphate groups in the protein. Commercial ovalbumin, such as the type used in this 
study, contains 0-2 mol PO4 covalently bound per mol of protein [25]. 
Self-encapsulation of ovalbumin was also monitored by confocal microscopy. 
Microspheres were made fluorescent by addition of rhodamine 6G into the polymer phase 
during microsphere preparation, and the self-encapsulation process was carried out with 
Alexa Fluor 448-ovalbumin. Incorporation of the protein into the microspheres was 
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confirmed by confocal microscopy (Figure 2b). Orthogonal images verified that protein 
was internal to the microspheres and not on the particle surface. 
2.4.3 Release of Encapsulated Ovalbumin 
Sustained release of ovalbumin from the microspheres was observed over a 49-
day period, with a moderate burst release of 28% (Figure 3). Ovalbumin in the in vitro 
release media was quantified by SE-HPLC, and the % cumulative release over time was 
calculated based on the mass of ovalbumin loaded into the microspheres. By the end of 
the study at day 49, 70% of the encapsulated ovalbumin was released. 
At the conclusion of the release study, the remaining unreleased ovalbumin was 
extracted from the polymer and desorbed from the CaHPO4 gel. The fraction of soluble 
and insoluble (covalent and non-covalent aggregates) remaining was determined. No 
unreleased soluble ovalbumin was detected, however a small fraction of insoluble 
aggregates (3%) was discovered after extraction (data not shown). Following mass 
balance, a total of 73% of the encapsulated ovalbumin was accounted for after the study. 
The stability of ovalbumin at the temperatures of self-encapsulation was studied 
by incubating the protein in loading solution buffer at the different process temperatures 
for the specified periods (Figure 4). Samples of ovalbumin were treated separately at (1) 
4°C for 24 hours, (2) 25°C for 24 hours, (3) 42°C for 48 hours, and (4) 4°C (24 hours) + 
25°C (24 hours) + 42°C (48 hours) (the full self-encapsulation process). A separate 
sample of protein was also incubated at 80°C for 24 hours to purposefully induce 
denaturation and aggregation [26]. As can be seen from the overlaid HP-SEC 
chromatograms of the samples in Figure 4, aggregation of the protein was not observed 
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during the self-encapsulation process, as compared to the protein sample denatured at 
80°C. 
2.4.4 Antigenic Ovalbumin Released from Microspheres 
The stability of the ovalbumin released from the microspheres was analyzed by 
measuring the antigenicity of the protein by ELISA. Previous work from our lab has 
shown improved stability of protein loaded by self-encapsulation compared to traditional 
encapsulation methods. Self-encapsulated tetanus toxoid maintained >96% of its 
antigenic activity over 28 days of release compared to only 27% for tetanus toxoid loaded 
by a traditional w/o/w method [10]. 
The antigenicity of released ovalbumin was measured over 21 days. The protein 
was analyzed by HP-SEC to measure total protein released and by ELISA to determine 
the fraction of released protein that was antigenic. From the plots shown in Figure 5, 
there was excellent agreement between measured total protein release and antigenic 
protein. This suggests that self-encapsulation of the ovalbumin did not negatively affect 
the stability of the model antigen. 
2.4.5 Serum and Mucosal Antibody Response in Mice Following Intranasal 
Immunization with Microspheres 
Female C57BL/6 mice were immunized via intranasal administration of 
microspheres loaded with OVA (10 µg OVA per dose). A booster dose was given three 
weeks later after primary immunization (Figure 6). The immune response generated by 
immunization with microspheres was compared to that for naïve mice (PBS control 
group) and mice immunized with cholera toxin B (CTB) (10 µg CTB + 10 µg ovalbumin). 
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Cholera toxin is a gold-standard adjuvant for stimulation of mucosal immune response in 
pre-clinical studies, but its use is limited due to its toxicity in humans [27]. The B subunit 
of cholera toxin maintains intranasal adjuvanticity but lacks the toxicity of the whole 
toxin [28].  
Intranasal immunization is an attractive route for vaccine administration since the 
nasal cavity is easily accessible and has a high density of dendritic cells [29]. Intranasal 
vaccination has shown the ability to produce an antibody response in the serum and in 
both local and distal mucosal secretions [30]. Since many infections occur at mucosal 
surfaces, induction of a mucosal immune response is important for protection against the 
infectious agent [31].  
Following prime and booster intranasal immunization of mice, the serum anti-
ovalbumin antibody response was measured (Figure 7). The total IgG response was 
analyzed (Figure 7a), as well as titers for IgG1 and IgG2C subclasses (Figures 7b and 7c, 
respectively). Subclass titers provide information about the polarization of the Th 
response, with IgG1 associated with a Th2-type response and IgG2C associated with a Th1 
response ([32], [33]). For both the CTB- and microsphere-immunized mice, the post-
prime antibody response was not significantly different than the baseline response 
produced by the PBS control group. However, a significant total IgG and IgG1 response 
was observed for both groups following booster administration. The response following 
immunization with microspheres approached that for the mice immunized with CTB, a 
strong mucosal adjuvant. Neither group displayed a significant IgG2C response after 
prime or boost vaccination, suggesting that the response for both groups was Th2-biased. 
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This is confirmed in the literature since CTB is known to trigger a more Th2-type 
response ([34], [35]).  
Apart from systemic immunity, local mucosal response was also analyzed by 
determining anti-ovalbumin antibody titers in bronchial alveolar lavage fluid collected 
after booster administration (Figure 8). The mucosal antibody response reflected the 
serum response in that a Th2-bias was observed due to predominant anti-ovalbumin IgG1 
titers and no detectable levels of IgG2C. In addition, the IgG and IgG1 antibody titers for 
the microsphere-immunized group once again approached the response generated by the 
CTB-immunized mice. No detectable levels of anti-ovalbumin IgA were found in the 
lavage fluid (data not shown), indicating a stronger systemic versus mucosal response to 
intranasal immunization. 
2.4.6 Cytokine Response after Ex Vivo Stimulation of Splenocytes 
The immune response was further assessed by studying the cytokine profiles of 
splenocytes restimulated ex vivo. Splenocytes were collected from immunized mice three 
weeks after booster administration and restimulated with whole ovalbumin and MHC 
class I- and II-restricted ovalbumin peptides. Splenocytes from CTB-immunized mice 
produced significant levels of IL-2, IL-6, IL-10, and IFN-γ compared to the PBS control 
group (Figure 9). While splenocytes from microsphere-immunized mice secreted 
detectable levels of the four cytokines, only IL-10 was produced at a statistically 
significant level compared to the control group. IL-2 and IFN-γ are secreted by Th1 cells, 
while IL-6 and IL-10 are indicative of a Th2-skewed response ([36], [37]). Hence, the 
cytokine results confirm the Th2-biased response suggested by the serum and mucosal 
antibody data for the microsphere-immunized mice. 
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2.5 Conclusions 
Active self-encapsulation of protein within PLGA microspheres is a promising 
alternative approach to traditional encapsulation techniques. Conventional encapsulation 
methods subject the protein to detrimental conditions that can cause instability and loss of 
antigenicity. Previous work by our group has shown improved stability of vaccine 
antigen loaded into microspheres by self-encapsulation [10].  
This study built upon our previous work to develop a formulation of self-
encapsulating microspheres for vaccine delivery, which showed unprecedented stability 
of tetanus toxoid in PLGA [10]. The formulation used in this study demonstrated the 
ability to maintain the antigenicity of released model antigen and generated encouraging 
results from a proof-of-concept intranasal immunization study. This research motivates 
further investigation of this formulation for delivery of clinically relevant antigens.  
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2.6 Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-1. SEM images of the self-encapsulation of OVA by PLGA microspheres 
loaded with CaHPO4 adjuvant gel as the protein-trapping agent. Images were taken prior 
to self-encapsulation of OVA (A) and after encapsulation of OVA and pore healing (B). 
Scale bars represent 5 μm. 
 
OVA loading at 4 and 25°C 
PLGA pore healing at 42°C 
A 
B 
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Table 2-1. Composition, size, and zeta potential of the self-encapsulating PLGA 
microsphere formulation. Data represent mean ± SEM, n = 3. 
PLGA 
concentration 
(mg in 1 mL) 
Volume of 
inner 
water 
phase (mL) 
Trehalose 
loading 
(wt. %)
a
 
Measured 
CaHPO4 
loading 
(wt. %)
b
 
Volume 
median 
diameter 
(µm) 
Zeta 
potential 
(mV) 
50 0.1 5 2.2 ± 0.1 7.05 ± 0.31 -21.9 ± 2.1 
 
a 
Theoretical loading
 
b
 Theoretical loading = 5 wt. % 
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Table 2-2. Active self-encapsulation of ovalbumin (OVA) by PLGA microspheres. Self-encapsulation was performed 
sequentially at 4, 25, and 42°C to load ovalbumin into the microspheres and then heal the polymer pores. Data represent mean 
± SEM, n = 3. 
 
Loading Solution OVA Loading 
Mass of 
microspheres 
in sample 
(mg) 
OVA 
concentration 
(mg/mL) 
Volume 
(mL) 
Theoretical 
% (w/w) 
loading
a
 
Measured  
% (w/w) 
loading 
%  
Encapsulation 
efficiency
b
 
Capacity of 
CaHPO4 
within 
microspheres
c,d
 
Capacity of 
unencapsulated 
CaHPO4 gel
c,e
 
20 0.5 0.4 1.0 0.60 ± 0.05 55.6 ± 6.0 0.27 ± 0.03 0.209 ± 0.004 
 
a 
(mg of total OVA in loading solution)/(mg of microspheres in sample + mg of total OVA in solution) 
b 
Efficiency relative to original mass of ovalbumin in loading solution 
c
 mg OVA loaded/mg CaHPO4 gel 
d
 Based upon the determined mass of CaHPO4 gel loaded within the microspheres  
e
 Determined for OVA loaded onto unencapsulated CaHPO4 gel 
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Figure 2-2. (A) Confocal microscopy (fluorescent and brightfield image overlay) of the 
distribution of calcium phosphate gel (violet) in microspheres. The gel was pre-loaded 
with Alexa Fluor 647-ovalbumin prior to incorporation in the inner water phase for 
microsphere production. (B) Confocal microscopy image of the distribution of Alexa 
Fluor 647-ovalbumin (violet) loaded within rhodamine-labeled PLGA microspheres 
(cyan) by self-encapsulation. Orthogonal images are shown in the right and bottom panel. 
Scale bar represents 10 μm. 
 
A 
B 
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Figure 2-3. Cumulative ovalbumin released as a function of time by self-encapsulating 
PLGA microspheres. In vitro release was conducted in PBS (pH 7.4) at 37°C. Data 
represent mean ± SEM (n = 3).  
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Figure 2-4. HP-SEC chromatograms of ovalbumin incubated in MOPS buffer at different 
temperatures. The overlaid black curves represent ovalbumin incubated at the 
temperatures of the self-encapsulation protocol individually and as one process (4°C for 
24 hours, 25°C for 24 hours, 42°C for 48 hours, and 4°C (24 hours) + 25°C (24 hours) + 
42°C (48 hours)). The red curve represents ovalbumin treated at 80°C for 24 hours to 
denature the protein. 
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Figure 2-5. Plot of OVA released over a 21-day period from microspheres as measured 
by HP-SEC () and ELISA (). ELISA analysis was performed to specifically measure 
the antigenic OVA present in the release samples. 
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Figure 2-6. Timeline for the intranasal immunization study. 
 
 
 
 
 
 
 
 
 
Day 0 
• Primary immunization 
Day 20 
• Serum collection for antibody analysis 
Day 21 
• Booster immunization 
Day 41 
• Serum collection for antibody analysis 
Day 42 
• Bronchial alveolar lavage for mucosal 
antibody response 
• Splenocyte collection for cytokine analysis 
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Figure 2-7. Serum anti-OVA antibody titers for groups on days 20 (prime response) and 
41 (boost response). (A) IgG, (B) IgG1, and (C) IgG2C. Data were fit using a 4-parameter 
curve, and titers were calculated by solving for the inverse dilution factor resulting in an 
absorbance value of 0.5. Data represent mean ± SEM (n = 10). All groups were compared 
using two-way ANOVA followed by Bonferroni’s post-test (*p ≤ 0.05, **p ≤ 0.01, ***p 
≤ 0.001, and ****p ≤ 0.0001). N.B. = no binding detected. 
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Figure 2-8. Anti-OVA antibody titers from bronchial alveolar lavage (BAL) samples 
collected from groups on day 42. Data were fit using a 4-parameter curve, and titers were 
calculated by solving for the inverse dilution factor resulting in an absorbance value of 
0.5. Data represent mean ± SEM (n = 9). All groups were compared using two-way 
ANOVA followed by Bonferroni’s post-test. Statistical significance shown is in relation 
to the corresponding PBS control (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, and ****p ≤ 
0.0001). N.B. = no binding detected. 
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Figure 2-9. Analysis of cytokines produced from mouse splenocytes restimulated ex vivo 
with whole OVA protein and MHCI or MHCII OVA peptide. Splenocytes from 
intranasally immunized mice were collected three weeks post booster immunization. Data 
represent mean ± SEM (n = 5). All groups were compared using two-way ANOVA 
followed by Bonferroni’s post-test (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, and ****p ≤ 
0.0001).  
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Chapter 3 
Self-Encapsulating PLGA Microspheres for Delivery to 
Antigen-Presenting Cells and Immune Response 
Following Subcutaneous Immunization 
3.1 Abstract 
Antigen internalization and processing by antigen-presenting cells (APCs) is 
necessary for the induction of the adaptive immune response. Hence, antigen delivery 
directly to APCs is a major focus of vaccine development in an effort to promote a 
stronger immune response. Poly(lactic-co-glycolic acid) (PLGA) nano- and microspheres 
have been explored for this purpose due to their particulate nature and ability to be 
internalized by APCs. In previous work, we described the development of a formulation 
of self-encapsulating PLGA microspheres for vaccine delivery. Self-encapsulation is a 
method developed for the remote loading of antigen into pre-made PLGA microspheres, 
which has shown the ability to improve the maintenance of antigenicity of encapsulated 
protein. Here, we expand upon the formulation for delivery of vaccine antigens. We 
investigated the internalization of the microsphere formulation by dendritic cells, and 
then studied the type and magnitude of the immune response generated by the 
microspheres after subcutaneous immunization in mice. Our results show successful 
uptake of the formulation, with a median particle diameter of 7.05 ± 0.31 µm, by a 
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murine dendritic cell line. Subcutaneous immunization of mice with ovalbumin-loaded 
microspheres induced an ovalbumin-specific CD8
+
 T cell response and IgG subclass 
titers indicative of a mixed Th1/Th2 response. The formulation was found to perform 
better than Alhydrogel® at stimulating a cellular response and producing anti-ovalbumin 
IgG2C titers. Additionally, mice given a single-dose of microspheres (containing twice the 
amount of antigen) generated a stronger CD8
+
 T cell response and comparable antibody 
response to two doses of Alhydrogel®. These results suggest that this formulation of self-
encapsulating microspheres has potential for further development for vaccine delivery. 
3.2 Introduction 
The goal of vaccination is to induce a specific, protective immune response and 
long-term immunity [1]. Generation of the appropriate type of immune response for the 
disease or pathogen at hand is essential for vaccine efficacy. For example, an antibody or 
Th2-based response is more effective against extracellular pathogens, whereas a cellular 
or Th1-type response is generally desired against cancer and intracellular pathogens [2]. 
In reality, the immune response against a particular disease or pathogen may be a mixture 
of these responses, with one being more predominant [3]. 
The method of antigen presentation by a vaccine has a significant effect on the 
type of response that will ensue. Antigen-processing cells (APCs) are the link between 
innate and adaptive immunity and are a major target for vaccine delivery. APCs process 
exogenous (e.g. bacterial antigens) and endogenous antigen (e.g. tumor and viral 
products) and display it on the cell surface to be recognized by other immune cells. 
Exogenous antigens are processed and presented on the cell surface in context of major 
histocompatibility complex (MHC) class I molecules for recognition by CD8
+
 T cells, 
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resulting in a cell-based response ([4], [5]). On the other hand, endogenous antigens are 
presented with MHC class II molecules and are recognized by CD4
+
 T cells, which 
results in a humoral response ([4], [5]). Some APCs, such as dendritic cells, can also 
undergo cross-presentation, whereby exogenous antigen is presented with MHC class I 
[4]. However, the exact mechanism of cross-presentation is not fully understood. 
Understanding the importance of antigen-APC interaction, much research has 
gone into improving the uptake of antigen by APCs for immune processing. In particular, 
polymeric micro/nanoparticle antigen delivery systems have been an intense area of focus 
due to their ability to (1) act as a depot to prolong the exposure of the antigen to the 
immune system, (2) be internalized by APCs for direct delivery of the antigen, and (3) 
potentially induce cross-presentation of antigen [6]. Poly(lactic-co-glycolic acid) has 
been the polymer of choice due to its biodegradable and biocompatible nature and ability 
for tunable, controlled release of antigen [7]. 
One notable challenge of PLGA particles is the potential for antigen instability, 
which can occur during particle production and antigen release, amongst other stages of 
the particle lifetime ([8], [9]). Traditional methods for loading the antigen into the 
particles can expose the antigen to detrimental conditions, including shear stress and oil-
water interfaces ([8],[10]). As a result, these conditions may lead to protein aggregation 
and unfolding, potentially causing significant loss of protein antigenicity ([11], [12]).  
Our group has developed a method for protein loading into PLGA microspheres 
that bypasses many of the challenges of traditional techniques ([8], [10]). This method, 
termed “self-encapsulation,” loads antigen by simple mixing of pre-made microspheres in 
an aqueous solution of protein. These microspheres contain an interconnecting pore 
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network and a protein-trapping agent (e.g. aluminum or calcium adjuvant gel) that is 
accessible through the pores. During mixing, the antigen diffuses into the pores and binds 
to the trapping agent. We have found that addition of a protein-trapping agent within the 
microspheres improves encapsulation efficiency compared to microspheres without a 
trapping agent ([10], [8]). Subsequent heating of the system above the glass-transition 
temperature (Tg) of the polymer causes pore closure, sealing the antigen inside the 
microspheres. We have shown improved antigenicity of tetanus toxoid released from self-
healing microspheres over 28 days compared to that loaded by traditional techniques [8]. 
Here we expand upon previous work in which we developed a self-encapsulating 
formulation of PLGA microspheres for vaccine delivery (see Chapter 2). The goal of this 
investigation was to study the ability of the microspheres to be internalized by dendritic 
cells, which are known as “professional” APCs as they are the most potent activators of T 
cells [13]. In addition, we studied the immune response generated by the microsphere 
formulation after subcutaneous administration in mice using ovalbumin as a model 
antigen. 
3.3 Materials and Methods  
3.3.1 Materials 
PLGA 50:50 (i. v. = 0.60 dL/g, Mw = 53.4 kDa, ester terminated) was purchased 
from Lactel (Durect Corporation, USA). Poly(vinyl alcohol) (PVA) (88% hydrolyzed, 
Mw = 25 kDa) was purchased from Polysciences Inc. (USA). Ovalbumin grade V, 
rhodamine 6G, and Triton-X 100 were purchased from Sigma (USA). Alpha-MEM, L-
glutamine, penicillin/streptomycin, fetal bovine serum (FBS), recombinant mouse 
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granulocyte-macrophage colony-stimulating factor (GM-CSF), DAPI, Alexa Fluor 647-
phalloidin, and ACK lysis buffer were purchased from Invitrogen (USA). 
Paraformaldehyde 40% was purchased from Electron Microscopy Sciences (USA). 
Alhydrogel® and Endofit OVA for immunization studies were purchased from Invivogen 
(USA). Biotinylated goat anti-mouse IgG, IgG1, and IgG2C were purchased from 
Southern Biotech (USA). All other reagents and solvents were purchased from 
commercial suppliers and were of analytical grade or higher.  
3.3.2 Preparation of CaHPO4 Adjuvant Gel 
CaHPO4 adjuvant gel was prepared as described in [14]. Equal parts Na2HPO4 
and CaCl2
 
were rapidly mixed together, and the pH immediately adjusted to 6.8-7.0 with 
NaOH. The resulting precipitate was washed 5 times with sterile 0.9% NaCl to remove 
excess phosphate and then resuspended in 0.9% NaCl to the desired concentration.  
3.3.3 Preparation of Self-Encapsulating PLGA Microspheres 
Porous self-encapsulating PLGA microspheres were prepared by the w/o/w 
double emulsion-solvent evaporation technique. Calcium phosphate adjuvant gel 
(CaHPO4) was included as a protein-trapping agent and trehalose as a porosigen. The 
inner water phase contained calcium phosphate gel (28 mg/mL) and trehalose (28 
mg/mL) in 25 mM succinate buffer (pH 4.0). One hundred microliters of inner water 
phase was added to 1 mL of 50 mg/mL PLGA in methylene chloride. The mixture was 
sonicated at 50% amplitude for 1 minute using a Sonics Vibra-Cell VC130 Ultrasonic 
Processor (Sonics & Materials Inc., USA) to form the first emulsion. Four milliliters of 
5% (w/v) PVA solution (used as an emulsion stabilizer) was added to the primary w/o 
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emulsion and the mixture was vortexed (Genie 2, Scientific Industries Inc., USA) for 30 
seconds to produce the w/o/w double emulsion. The w/o/w emulsion was poured into 100 
mL of chilled 0.5% (w/v) PVA under rapid stirring and hardened at room temperature for 
6 hours. Microspheres were passed through a 10-µm mesh sieve and the filtrate was 
collected and centrifuged (7000 rpm for 5 minutes). The microspheres in the pellet were 
washed repeatedly with double-distilled (dd) H2O and then lyophilized (FreeZone 2.5, 
Labconco, USA).  
3.3.4 Determination of CaHPO4 Loading by ICP-OES  
Loading of CaHPO4 in PLGA microspheres was determined by inductively 
coupled plasma-optical emission spectrometry (ICP-OES). Briefly, approximately 10 mg 
of microspheres were added to 1 mL acetone, vortexed, and then centrifuged at 7000 rpm 
for 5 minutes. The supernatant polymer solution was removed and the pellet was washed 
twice more with 1 mL acetone. The resulting residue was dried in a fume hood to allow 
for evaporation of the acetone. One milliliter of 30% HCl was added to each sample to 
dissolve the residue. The samples were then diluted with ddH2O to bring the theoretical 
concentration of Ca ion in the samples to between 1 and 15 ppm. The concentration of Ca 
ion was then analyzed by ICP-OES (Perkin-Elmer Optima 2000 DV with Winlab 
software). Each sample was measured three times and analysis was done in triplicate.  
3.3.5 Scanning Electron Microscopy 
The surface morphology of microspheres was examined using a Hitachi S3200N 
scanning electron microscope (SEM) (Hitachi, Japan). Briefly, lyophilized microspheres 
were fixed on a brass stub using double-sided carbon adhesive tape. The sample was 
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made electrically conductive by coating with a thin layer of gold for 120 seconds at 40 W 
under vacuum. Images were taken at an excitation voltage of 8.0 kV. EDAX® software 
was used to obtain the final image.  
3.3.6 Microsphere Size and Zeta Potential Analysis 
The volume median diameter of the microspheres was measured using a 
Mastersizer 2000 (Malvern Instruments Ltd, UK). Ten milligrams of lyophilized 
microspheres were suspended in 5 mL 0.5% PVA solution and briefly vortexed. Six 
measurements were performed per sample at a stir speed of 2000 rpm and sampling time 
of 15 seconds. Zeta potential was measured with a Zetasizer Nano ZSP (Malvern 
Instruments Ltd, UK). Lyophilized microspheres were suspended in ddH2O (0.1% mass) 
and placed in a disposable folded capillary zeta cell (Malvern Instruments Ltd, UK). Each 
sample was measured six times.  
3.3.7 Active Self-Encapsulation of Ovalbumin by PLGA Microspheres 
Active encapsulation of ovalbumin (OVA) by PLGA microspheres was carried 
out in two phases: an initial incubation of the porous microspheres in protein solution at a 
temperature below the polymer Tg for protein sorption onto the CaHPO4 gel, and then 
incubation at a temperature above the Tg for the polymer pores to heal. Briefly, 
approximately 20 mg of lyophilized microspheres were incubated in an OVA solution 
(0.5 mg/mL OVA in 0.4 mL 10 mM MOPS buffer, pH 7.4) at 4°C for 24 hours and then 
25°C for 24 hours (T<Tg), followed by incubation at 42°C for 48 hours (T>Tg). 
Incubation was performed under constant agitation using a rigged rotator (Glas-Col, 
USA).  
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3.3.8 Determination of Protein Loading and Encapsulation Efficiency 
After self-encapsulation of the protein, the microsphere samples were centrifuged 
at 7000 rpm for 5 minutes. The supernatant was passed through a low protein-binding 
Durapore (PVDF) membrane-based syringe filter unit (Millipore Corporation, USA) and 
the filtrate collected. The microspheres were then washed once with ddH2O and the rinse 
filtered and collected. A modified Bradford assay was used to determine OVA 
concentration in the filtrates. Coomassie Plus® reagent (Thermo Fisher Scientific, USA) 
was added to the appropriate volume of standard OVA solution or filtrate sample in a 96-
well plate (Nunc, Thermo Scientific, USA). After 10 minutes, the absorbance was read at 
595 nm using a Dynex II MRX microplate reader (Dynex Technology Inc., USA). The 
mass of OVA encapsulated by the microspheres was calculated by subtracting the mass 
of OVA in the filtrates from the mass of OVA in the initial loading solution. Percent w/w 
loading and encapsulation efficiency (EE) were quantified with the following formulas:  
 
% w w⁄ loading: 
mass of OVA encapsulated by the microspheres
mass of microspheres in loading sample + 
mass of OVA encapsulated
×  100 
 
% EE: 
mass of OVA encapsulated by the microspheres
mass of OVA in initial loading solution
×  100 
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3.3.9 Evaluation of the In Vitro Release of Ovalbumin from Self-Encapsulating 
Microspheres 
Approximately 20 mg of OVA-encapsulated microspheres were incubated in 0.5 
mL PBS, pH 7.4, at 37 °C under constant agitation (240 rpm/min). At different 
incubation times (1, 3, 5, and 7 days, and then every 7 days until day 49), the mixture was 
centrifuged at 7000 rpm for 5 minutes and the supernatant was collected through a low 
protein-binding Durapore (PVDF) membrane-based syringe filter unit (Millipore 
Corporation, USA). Fresh release media (0.5 mL) was then added to the sample and the 
microspheres were resuspended to continue the release study. The OVA content in the 
supernatants was analyzed by size exclusion-high performance liquid chromatography 
(SE-HPLC).  
3.3.10 Size Exclusion-High Performance Liquid Chromatography (SE-HPLC) of 
Ovalbumin  
SE-HPLC was performed using a TSKgel G3000SWxl column (Tosoh Bioscience, 
USA) on a Waters HPLC system (Waters, USA). The mobile phase consisted of PBS, pH 
7.4, at a flow rate of 0.7 mL/min and injection volume of 50 µL. Protein detection by UV 
was done at 210 and 280 nm.  
3.3.11 Cell Lines and Tissue Culture 
JAWSII dendritic cell line, obtained from the bone marrow of C57BL/6 mice, was 
purchased from ATCC (USA, ATCC no. CRL-11904). Cells were cultured in complete 
alpha-MEM media supplemented with 2 mM L-glutamine, 100 μg/mL streptomycin, 100 
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U/mL penicillin, 20% FBS, and 5 ng/mL GM-CSF. Cells were maintained in a 
humidified incubator at 37°C and 5% CO2.  
3.3.12 Confocal Microscopy of Microsphere Internalization by Dendritic Cells 
JAWSII cells were treated with microspheres, and the internalization of the 
microspheres by the cells was visualized using confocal microscopy. Briefly, 
microspheres were made fluorescent by addition of rhodamine 6G to the oil phase during 
microsphere production to dye the polymer. Cells were plated in complete alpha-MEM at 
2 x 10
5
 cells/dish in a 35 mm culture dish with a glass coverslip on the base (MatTek 
Corporation, USA) and maintained in a humidified incubator at 37°C and 5% CO2. After 
overnight incubation, the media was aspirated from the dish to remove non-adherent cells. 
The cells were then incubated for 24 hours with 0.1 mg/mL fluorescent microspheres. 
After incubation, media was once again aspirated to remove non-internalized 
microspheres. The cells were fixed with 4% paraformaldehyde and permeabilized with 
0.1% Triton-X solution. The actin filaments were stained with Alexa Fluor 647-
phalloidin and the nucleus stained with DAPI. A Nikon A-1 spectral confocal microscope 
with NIS Elements software (Nikon Instruments) was used to view the sample. 
3.3.13 Flow Cytometry Analysis of Microsphere Internalization 
JAWSII cells were plated in a 12-well culture plate (Corning Inc., USA) at 1.5 x 
10
5
 cells/well in complete alpha-MEM. After overnight incubation at 37°C and 5% CO2, 
media was removed from the wells and fresh media was added containing different doses 
of rhodamine 6G microspheres (25, 50, or 100 µg/well). After 6 or 24 hours of incubation, 
the cells were washed with PBS and collected. The cells were fixed with 4% 
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paraformaldehyde and permeabilized with a BD Perm/Wash buffer (BD Biosciences, 
USA). Actin filaments were stained with a phalloidin-iFluor 405 dye (AAT Bioquest, 
Inc., USA) and analyzed with the Amnis ImageStream
x
 Mark II imaging flow cytometer 
(EMD Millipore Corporation, USA). 
3.3.14 Immunization Study 
Female C57BL/6 mice, 6-7 weeks old, were purchased from Harlan Laboratories, 
Inc. and handled according the University of Michigan Institutional Animal Care 
guidelines. Mice (5 mice per group) were immunized subcutaneously at the tail base with 
100 µL of sterile PBS, Alhydrogel® or CaHPO4 adjuvant gel co-administered with OVA 
(100 µg gel + 10 µg OVA), or microspheres loaded with OVA (10 or 20 µg OVA). A 
booster dose was given three weeks later on day 21 after primary immunization to all 
groups except for the group receiving microspheres at a dose of 20 µg OVA (only prime 
injection given). On days 20 and 42, blood samples were collected by submandibular 
bleed for analysis of serum antibody titers. Blood was collected into Microvette 500 Z-
Gel serum collection tubes (Sarstedt, Germany) and centrifuged at 10,000 x g for 5 
minutes to separate the serum. Serum was stored at -80°C until analysis. 
3.3.15 Measurement of Antibody Titers 
Serum samples were sent to the Immunology Core at the University of Michigan 
Cancer Center for ELISA analysis. The assays were performed using a standard ELISA 
protocol.  Briefly, OVA (10 µg/mL in carbonate/bicarbonate buffer) was used to coat 
384-well plates overnight at 4°C.  Plates were washed and residual binding sites blocked 
with 0.2% casein in Tris-buffered saline (TBS) for at least one hour.  The same buffer 
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was used for sample dilutions. Ig detection antibodies were minimally diluted to the 
manufacturer’s suggested working range. ELISA analysis was used to measure IgG, IgG1, 
and IgG2C response. 
3.3.16 CD8+ T Cell Tetramer Staining 
Seven days following booster immunization, blood was collected by 
submandibular bleed and collected in a BD Microtainer tube with dipotassium EDTA 
additive to prevent clotting (BD Biosciences, USA). Red blood cells were lysed with 
ACK lysis buffer and washed to isolate the peripheral blood mononuclear cells (PBMCs). 
The Fc receptor was blocked with CD16/32 (eBioscience Inc., USA). Cells were 
incubated with anti-CD8 and T-Select H-2Kb OVA Tetramer-SIINFEKL-PE (MBL, 
Japan), followed by staining with DAPI (Sigma-Aldrich, USA) to discriminate live from 
dead cells. A Beckman Coulter CyAn 5 flow cytometer (Beckman Coulter Inc., USA) 
was used to analyze the samples. Data was processed using FlowJo (FlowJo, USA).  
3.3.17 Statistical Analysis 
Statistical analyses were carried out using GraphPad Prism 6.0g software. One-
way ANOVA or two-way ANOVA with Bonferroni’s post-test were used to compare 
multiple groups. Values are reported as mean ± SEM (standard error of the mean).  
3.4 Results and Discussion 
3.4.1 Microsphere Preparation and Characterization 
Microspheres were prepared as described in Chapter 2. Briefly, the formulation 
was made using a standard double emulsion-solvent evaporation technique. Trehalose 
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was included in the inner water phase to act as a porosigen to create the interconnecting 
pore network that is necessary for protein diffusion into the microspheres during self-
encapsulation [10]. The microsphere morphology and size, CaHPO4 content, 
encapsulation of ovalbumin, and release profile were examined. The results were 
previously presented in Chapter 2. A brief summary of the results are provided in Table 1 
and discussed in the following sections. 
3.4.1.1 Formulation Morphology and Size 
The size of the microspheres is of particular importance for promoting 
internalization by APCs. From a number of studies that have been conducted, it has been 
demonstrated that microspheres of a size less than 10 µm are more efficiently internalized 
by APCs compared to larger particles ([15], [16], [17], [18] [19], [20]). The formulation 
parameters (including polymer concentration and energy of agitation) were refined to 
produce porous, spherical microspheres of the desired size range. Sonication was found 
to be preferable to homogenization for forming the primary emulsion, which was 
expected since greater agitation is known to generate smaller particles [21]. The median 
microsphere diameter for this formulation was found to be 7.05 ± 0.31 µm, with a zeta 
potential of -21.9 ± 2.1 mV (Table 1).  
3.4.1.2 Incorporation of CaHPO4 Gel and Encapsulation of Ovalbumin 
CaHPO4 adjuvant gel was used as the protein-trapping agent for the formulation. 
Calcium phosphate adjuvant is a natural constituent of the body and, hence, is well-
tolerated and readily resorbed [14]. The CaHPO4 gel was prepared by a rapid mixing 
method as described by Gupta et al. [14]. The gel was added to the inner water phase to 
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be incorporated into the microspheres during production. Using ICP-OES, the w/w 
loading of CaHPO4 within the microspheres was determined to be 2.2 ± 0.1 % (Table 1). 
The self-encapsulating ability of the microsphere formulation was tested by 
loading ovalbumin as a model antigen. The w/w loading was found to be 0.60 ± 0.05 %, 
with an encapsulation efficiency of 55.6 ± 6.0 % (Table 1). The w/w % loading for the 
formulation was within the expected range based upon the loading of the incorporated 
CaHPO4 gel within the microspheres and the loading capacity of the gel for the protein 
(see Chapter 2). The microsphere morphology prior to self-encapsulation was viewed by 
scanning electron microscopy (SEM) and was confirmed to be spherical with visible 
pores (Figure 1). Successful healing of polymer pores after self-encapsulation was 
confirmed by SEM (Figure 1). 
3.4.1.3 Sustained Release of Model Antigen 
The % cumulative release of ovalbumin from the microspheres is summarized in 
Table 1. The formulation produced a moderate burst release of 28.4 ± 1.5 %, with 
sustained release of protein over 6 weeks. Antigenicity of the protein was maintained 
during release, as confirmed by ELISA (see Chapter 2).  
3.4.2 Internalization of Microspheres by Dendritic Cells 
Antigen uptake and processing by APCs is necessary for presentation to other 
immune cells and induction of the adaptive immune response. Dendritic cells can be 
considered key APCs and are important for the generation of a primary immune response, 
i.e. the response upon first encounter of the immune system to the antigen, and 
subsequent immunological memory [22]. Depending on type of antigen, uptake by 
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dendritic cells can happen by receptor-mediated endocytosis, macropinocytosis and 
phagocytosis [23].  
Herein, we studied the ability of the microsphere formulation to be internalized by 
dendritic cells for direct antigen delivery. Dendritic cells are known to internalize PLGA 
particulates via phagocytosis [4]. To evaluate this interaction, we used confocal 
microscopy to visualize internalized microspheres and flow cytometry to measure particle 
uptake.  
3.4.2.1 Visualization of Microsphere Uptake Using Confocal Microscopy 
To view the uptake of the microsphere formulation by dendritic cells, fluorescent 
microspheres were incubated with JAWSII cells, a murine bone marrow-derived 
dendritic cell line. Microspheres were made fluorescent by the addition of rhodamine 6G 
to the polymer phase during production. The microspheres were then incubated with 
JAWSII cells for 24 hours at 37°C. To visualize cellular components, the nucleus was 
stained with DAPI and the actin filaments stained with Alexa Fluor 647-phalloidin. 
Samples were observed with a confocal microscope (Figure 2). 
As shown in Figure 2, the dendritic cells successfully internalized one or more 
microspheres over the 24-hour period. Both larger and smaller microspheres within the 
size distribution were taken up by the cells. Orthogonal images confirmed that 
microspheres were within the cells and not attached to the cell surface, as evidenced by 
the surrounding actin filaments.  
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3.4.2.2 Measurement of Particle Uptake by Flow Cytometry 
Microsphere internalization was additionally explored by flow cytometry to 
measure particle uptake. JAWSII cells were incubated with three different concentrations 
of rhodamine 6G-labeled microspheres over 6 and 24 hours at 37°C. Cells were treated 
with phalloidin-iFluor 405 dye to stain the actin filaments. An Amnis ImageStream
x
 
Mark II imaging flow cytometer was then used to quantify the percent of cells with 
associated rhodamine positivity (Figure 3a). Images obtained from the flow cytometer 
provided visualization of the counted cells and the associated microspheres (Figure 3b-e). 
From the results, a clear trend was observed in the data. As might be expected, the 
percent of microsphere-positive cells increased with both incubation time and 
microsphere concentration. This suggests that a longer incubation time and higher 
microsphere concentration promote microsphere-cell interaction, resulting in improved 
uptake. 
3.4.3 Subcutaneous Immunization with Ovalbumin-Loaded Microspheres  
Previously, we explored the immune response generated by the microsphere 
formulation in a proof-of-concept intranasal immunization study in mice (see Chapter 2). 
Here, we wanted to compare the response produced after subcutaneous administration of 
the microspheres. It has been shown that the route of administration plays a role in 
shaping the immune response, perhaps due to local cell types (e.g. different subsets of 
APCs) and stability of the microspheres by that administration method (e.g. particle 
agglomeration at the site of injection) [24]. 
The immunization study was designed to (1) determine the type and magnitude of 
the immune response induced by the microspheres, (2) compare the immune response 
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from the microspheres to that induced by commercial aluminum hydroxide adjuvant 
(Alhydrogel®), and (3) test the dose-sparing ability of the microspheres. C57BL/6 mice 
were immunized with Alhydrogel® or CaHPO4 adjuvant gel co-administered with OVA 
(100 µg gel + 10 µg OVA), or microspheres loaded with OVA (10 or 20 µg OVA). All 
groups were given a prime dose on day 0 and a booster dose three weeks later (Figure 4), 
except for the microsphere group with 20 µg OVA. The latter group was given as a 
prime-only dose to test the duration of the immune response by single-dose 
administration. 
Aluminum hydroxide was included in the study since it has become the reference 
for new adjuvants for use in humans [25]. It has been used in human vaccines since the 
1920s and is one of the few widely-approved adjuvants ([26], [27]). The adjuvant is 
known to cause a more Th2-biased immune response, and is thought to act by prolonging 
antigen exposure to the immune system, improving antigen uptake by APCs, and 
increasing the expression and duration of MHCII complexes ([28], [26]).  
3.4.3.1 CD8+ T Cell Response 
On day 28, four weeks after prime dosing and one week following booster, 
peripheral blood mononuclear cells (PBMCs) were collected to measure the ovalbumin-
specific CD8
+
 T cell response, a measure of the cellular response generated (Figure 5). Of 
the groups tested, Alhydrogel® and microspheres (both the 10 µg and 20 µg OVA doses) 
produced a significant CD8
+
 T cell response above that of the PBS control group. The 
group immunized with calcium phosphate adjuvant did not generate a cellular response 
above baseline.  
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The microsphere group with 10 µg of OVA produced the strongest ovalbumin-
specific CD8
+
 T cell population of the three groups, having a significantly higher cellular 
response compared to that produced by Alhydrogel®. In addition, the microsphere group 
given as prime-only (20 µg of OVA) generated a cellular response comparable to that of 
the Alhydrogel®, which was given to mice at both prime and boost. This data indicates 
that the microspheres are capable of inducing a significant antigen-specific cellular 
immune response compared to Alhydrogel®, which acted as a reference commercial 
adjuvant. Further, the microspheres demonstrate promising single-injection ability since 
microspheres given by one injection (with twice the amount of antigen) produced a 
similar cellular response to commercial adjuvant given by two separate injections. 
3.4.3.2 Serum Antibody Titers 
The serum anti-ovalbumin antibody response was analyzed following both prime 
and booster immunization of mice (Figure 6a-c). Total IgG and titers for IgG1, and IgG2C 
subclasses were measured. IgG subclass titers provide information about the polarization 
of the Th response, with IgG1 associated with a Th2-type response and IgG2C associated 
with a Th1 response ([29], [30]).  
All groups produced antibody titers significant from baseline after both prime and 
booster immunization, except for the post-prime IgG2C response (all groups at baseline). 
For the total IgG response, the Alhydrogel® and microsphere groups generated 
comparable post-prime and post-boost titers, though the post-boost response for the two-
dose microsphere group was higher than that for the single-dose group. Similarly, the 
prime and booster IgG1 titers were comparable for all groups, however the mean post-
boost titer for the two-dose microsphere group was higher than that produced by 
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Alhydrogel®. Finally, the mean post-booster IgG2C titer for the two-dose microsphere 
group was significantly higher than for the other groups. The mean titer for the single-
dose of microspheres was comparable to the titers achieved by the Alhydrogel® and 
calcium phosphate groups.  
Taking into account all of the antibody data, administration of two doses of the 
microspheres loaded with ovalbumin resulted in a mixed Th1/Th2 immune response that 
was stronger in comparison to two doses of ovalbumin co-administered with 
Alhydrogel®. Additionally, the Th1/Th2 response induced by the single-dose 
microsphere treatment was comparable to two doses of the Alhydrogel® adjuvant. This 
data suggests that the microspheres can induce a stronger Th1/Th2-associated response 
compared to Alhydrogel® when given by the same number of doses, or produce a 
comparable response when twice the amount of antigen is given by a single dose. Single-
injection ability is desired for a vaccine due to potential improvements in convenience 
and patient compliance, particularly in low-resource settings. 
3.5 Conclusions 
In previous work, we developed and characterized a formulation of self-
encapsulating microspheres for vaccine delivery (see Chapter 2). In this chapter, we 
expand upon that research by studying the ability of the microspheres to be internalized 
by antigen-presenting cells, for direct delivery of antigen to APCs, and investigate the 
type and magnitude of the immune response generated by the formulation following 
subcutaneous administration in mice.  We compared immunization with our microsphere 
formulation to Alhydrogel® as a standard commercial adjuvant for human vaccines. 
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Our results show that the self-encapsulating microspheres, with a median diameter 
of 7 µm, are successfully internalized by a murine dendritic cell line and are capable of 
producing a mixed humoral and cellular immune response against ovalbumin following 
subcutaneous immunization. Two-dose immunization with the microspheres generated an 
improved CD8
+
 T cell response and Th1/Th2-mixed response compared to two doses of 
Alhydrogel®. Further, a single dose of microspheres, containing twice the amount of 
antigen, produced a stronger cellular response and comparable antibody response to two 
doses of Alhydrogel®. In conclusion, this formulation demonstrates excellent potential 
for further development for vaccine delivery.  
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3.6 Figures 
 
 
Figure 3-1. SEM images of self-encapsulating PLGA microspheres containing CaHPO4 
adjuvant gel as the protein-trapping agent. Microspheres are shown before (left) and after 
(right) self-encapsulation of ovalbumin and pore healing. Scale bars represent 5 μm. 
 
 
 
 
 
 
 
 
 
 
 
 
Before After 
  85 
Table 3-1. Summary of the properties of the self-encapsulating microsphere formulation. 
Data are shown as mean ± SEM (n = 3). 
 
Microsphere composition, size, and zeta potential 
Measured CaHPO4 loading (wt. %) 2.2 ± 0.1 
Volume median diameter (µm) 7.05 ± 0.31 
Zeta potential (mV) -21.9 ± 2.1 
  
OVA loading by self-encapsulation 
% (w/w) loading 0.60 ± 0.05 
% Encapsulation efficiency 55.6 ± 6.0 
  
% Cumulative release of OVA from microspheres 
Day 
1 28.4 ± 1.5 
21 49.6 ± 1.1 
28 54.2 ± 0.1 
42 66.5 ± 1.4 
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Figure 3-2. Confocal microscopy image showing healed rhodamine-labeled self-
encapsulating microspheres (green) internalized by JAWSII dendritic cells after 24 hours 
of incubation. Actin filaments were stained with Alexa Fluor 647-phalloidin (violet) and 
nuclei were stained with DAPI (blue). Scale bar represents 10 µm. 
 
 
 
 
 
 
 
 
 
  87 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-3. Internalization of microspheres by JAWSII dendritic cells over time. (A) 
Flow cytometry analysis (Amnis ImageStream
x
 Mark II) of JAWSII cells treated with 
different doses of rhodamine 6G-labeled microspheres over two incubation times. 
Columns show the percent of gated events containing cells with associated microspheres. 
Data represent mean ± SEM (n = 3). (B-E) Representative images of those obtained by 
ImageStream
x
 analysis. (B) Bright-field image of the cell with associated microspheres; 
(C) and (D) fluorescent images of the microspheres (dyed with rhodamine 6G) and 
JAWSII cells (stained with phalloidin-iFluor 405), respectively; and (E) overlay of 
images B-D. 
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Figure 3-4. Timeline for the subcutaneous immunization study. 
 
 
 
 
 
 
  
 
Day 0 
• Primary immunization 
Day 20 
• Serum collection for antibody analysis 
Day 21 
• Booster immunization 
Day 28 
• PBMC collection for tetramer staining to 
measure OVA-specific CD8+ T cells 
Day 42 
• Serum collection for antibody analysis 
  89 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-5. Plot of % SIINFEKL-tetramer+ among CD8
+
 T cells in PBMCs for the test 
groups on day 28. Groups given prime and booster doses are marked (x 2), while (x 1) 
denotes that only a prime injection was administered. Data represent mean ± SEM (n = 5). 
All groups were compared using one-way ANOVA followed by Bonferroni’s post-test 
(*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001,and ****p ≤ 0.0001).  
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Figure 3-6. Serum anti-OVA antibody titers for groups on days 20 (prime response) and 
42 (boost response). (A) IgG, (B) IgG1, and (C) IgG2C. Groups given prime and booster 
doses are marked (x 2), while (x 1) denotes that only a prime injection was administered. 
Data were fit using a 4-parameter curve, and titers were calculated by solving for the 
inverse dilution factor resulting in an absorbance value of 0.5. N.B. = no binding detected. 
Data represent mean ± SEM (n = 5). All groups were compared using two-way ANOVA 
followed by Bonferroni’s post-test (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001,and ****p ≤ 
0.0001). 
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Chapter 4 
Conclusion 
4.1 Significance 
This thesis presents the first application of the self-encapsulation paradigm 
developed by our lab to the delivery of vaccine antigens in cell culture and mammalian 
subjects.  Our previous work focused on the development of the self-encapsulation 
approach for conventionally larger, non-phagocytosable microspheres and the study of 
antigen stability after encapsulation by this process and subsequent release ([1], [2]). 
Confirming the ability of self-encapsulation to improve the antigenicity of loaded protein 
compared to traditional methods, we designed a formulation of self-encapsulating 
microspheres specifically for vaccine delivery that would promote delivery of antigen to 
antigen-presenting cells (APCs). 
The results from this work illustrate a few key findings and support the thesis 
hypothesis. The microsphere formulation (1) provided sustained release of antigenic 
model protein over several weeks, far better than conventional microspheres prepared by 
solvent evaporation; (2) was successfully internalized by dendritic cells, the primary 
APCs for adaptive immunity; (3) was capable of inducing mixed Th1/Th2 immunity and 
an antigen-specific CD8
+
 T cell (cellular) response; (4) performed better than 
Alhydrogel® after subcutaneous delivery at achieving both cellular and humoral 
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immunity; and (5) has the potential for single-time injection. These findings address 
certain challenges of traditional encapsulation techniques and vaccine delivery. 
The ability of the formulation to maintain protein antigenicity during release, 
particularly over multiple weeks, is a major advantage that is challenging for traditional 
encapsulation methods. As discussed, traditional techniques expose the antigen to 
destabilizing conditions, leading to aggregation and loss of structure and having a 
detrimental effect on the antigenicity ([2], [1], [3], [4]). This formulation demonstrates 
that it can maintain the antigenicity of the protein cargo and prolong its exposure over 
many weeks.  
 Current strategies in vaccine development are focusing on improving the potency 
of the immune response (e.g. induction of cellular immunity) and improving vaccine 
coverage  (e.g. reducing dose burden) ([5], [6], [7]). This formulation shows promising 
results in regards to both challenges. The results achieved from the subcutaneous 
immunization study demonstrate a notable ability of the formulation to induce a CD8
+
 T 
cell response (i.e. cell-mediated response) and IgG subclass titers associated with a mixed 
Th1/Th2 response. In addition, microspheres administered by single-dose immunization 
performed comparably to commercial Alhydrogel® adjuvant given by two doses. This 
finding suggests the possibility of single-time injection, which is beneficial for 
convenience and patient compliance, particularly in resource-limited settings. 
4.2 Future Directions 
The self-encapsulating formulation developed through this research has shown 
potential as a vaccine delivery system. Further work should be conducted to go beyond a 
model antigen and apply the system to delivery of a clinically relevant antigen. For 
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example, one possibility is the recombinant hepatitis B surface antigen (HBsAg). The 
commercial hepatitis B vaccine, which consists of HBsAg adsorbed to aluminum 
adjuvant, requires three doses for efficacy [8]. The microsphere formulation could be 
tested for its single-time injection ability with the antigen in an attempt to minimize the 
doses required for protective immunity.  
Additionally, improvements to the immune response could be explored by 
incorporation of immunostimulators to enhance and direct the immune response against 
the antigen. Immunostimulators, such as cytokines and TLR ligands, can affect the 
balance of Th1/Th2 immunity [9]. For example, bacterial monophosphoryl lipid A 
(MPLA) and CpG oligodeoxynucleotides (ODN) have been shown to induce improved 
Th1-type immunity ([10], [11], [12]). In future work, addition of an immunostimulator to 
the microspheres, to be co-delivered with the antigen, would be worth exploring for 
enhancement of the protective immune response. 
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